Document:

<PAGE>   1
                                                                EXHIBIT 10.27(c)

                           EXCLUSIVE LICENSE AGREEMENT

         This Exclusive License Agreement (the "Agreement") is made as of May
16, 2000 (the "Effective Date") by and between LXR Biotechnology, Inc., a
Delaware corporation, having a place of business at 3095 Richmond Parkway, Suite
213, Richmond, CA 94806 ("LXR") and Introgen Therapeutics, Inc., a Delaware
corporation, having a place of business at 301 Congress Avenue, Suite 1850,
Austin, TX 78701 ("Introgen").

                                   BACKGROUND

         A. LXR owns certain Patent Rights and Related Technology (as defined
below) relating to the "bak" gene; and

         B. Introgen desires to obtain, and LXR desires to grant, an exclusive
license to Patent Rights and Related Technology (as defined below) subject to
the terms and conditions set forth herein below.

         NOW, THEREFORE, in consideration of the mutual covenants and promises
herein contained, the parties hereto agree as follows:

         1. DEFINITIONS. As used in this Agreement, the following capitalized
terms shall have the meanings indicated:

                  1.1 "Field" shall mean [*] of the "bak" gene in humans and the
discovery and development of methods, techniques and other subject matter for
[*] of the "bak" gene in humans, and shall include all fragments, derivatives
and splice variants of the "bak" gene; a "derivative" shall mean a nucleotide
sequence directly derived from the "bak" gene claimed in the Existing Patent
Rights as defined in Section 1.5.1, the gene product of which has apoptotic
activity substantially similar to that of the protein encoded by the "bak" gene.

                  1.2 "Patented Product" shall mean any product containing or
encompassing the "bak" gene, the manufacture, use or sale of which would, but
for the license granted under the License Agreement, infringe a Valid Claim of
the Patent Rights in the country where it is sold.

                  1.3 "Non-Patented Product" shall mean any product containing
or encompassing the "bak" gene that embodies Related Technology, but the
manufacture, formulation or use thereof is not the subject of any patent
application or patent, or any issued patents covering such product have been
abandoned or declared invalid in a non-appealable order.

                  1.4 "Licensed Product" shall mean any Patented Product or
Non-Patented Product.

                  1.5 "Patent Rights" shall mean any and all rights in:

LXR LICENSE AGREEMENT

[*]  Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       1
<PAGE>   2
                  1.5.1 all worldwide patents and patent applications claiming
the subject matter claimed in U.S. Patent Application numbers: [*], and any
foreign counterparts of the foregoing, existing or capable of being revived as
of the Effective Date (the "Existing Patent Rights"); and

                  1.5.2 all divisions, continuations, continuations-in-part,
foreign counterparts, patents of addition, and substitutions of, and all patents
issuing on any of the foregoing or of any patent application which claim
priority from any Existing Patent Rights, together with all registrations,
reissues, reexaminations, supplementary protection certificates or extensions of
any kind with respect to any of such patents.

                  1.6 "Related Technology" shall, subject to the provisions of
Section 1.1 (including the exclusions and limitations on the Field set forth
therein), mean all technical information, know-how, processes, procedures,
compositions, methods, techniques, data or other subject matter owned by LXR as
of the Effective Date, and relating to the manufacture, formulation, use or sale
of Licensed Products, and that are necessary or useful for the exercise of the
rights granted under the License Agreement.

                  1.7 "Valid Claim" shall mean any claim contained in any patent
application or in any issued patent included within the Patent Rights, which has
not been abandoned or declared invalid in a non-appealable order, as the case
may be, and which would be infringed by the manufacture, use, sale, offer for
sale or import of a Licensed Product in the absence of the license granted under
the License Agreement; provided that, in the case of a patent application that
has not issued, not more than ten (10) years has elapsed from the filing date to
which the claim is entitled.

                  1.8 "Net Sales" shall mean the gross amounts invoiced by
Introgen, its affiliates and sublicensees for the sale of Licensed Products to
unaffiliated third parties, less (i) all trade, cash and quantity discounts or
government rebates actually granted and taken; (ii) refunds, allowances or
credits to customers because of rejections or returns; (iii) prepaid freight,
sales taxes, duties and other governmental taxes (including value added tax);
and (iv) provisions for uncollectable accounts determined in accordance with
reasonable accounting practices, consistently applied to all products of the
selling party.

                  1.9 "Introgen Improvement" shall mean any invention solely
owned by Introgen consisting of compositions of the "bak" gene (i.e., fragments,
derivatives and splice variants of the "bak" gene covered under Patent Rights)
or methods of using the "bak" gene (including fragments, derivatives and splice
variants thereof) and all intellectual property rights (including patent
applications and patents) therein.

LXR LICENSE AGREEMENT

[*]  Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       2
<PAGE>   3
         2. GRANTS AND OBLIGATIONS

                  2.1 LXR grants to Introgen an exclusive, worldwide license,
with the right to grant and authorize sublicenses, under the Patent Rights and
Related Technology to make, have made, use and sell Licensed Products, practice
any method, process or procedure and otherwise exploit the Patent Rights and
Related Technology, and to have any of the foregoing performed on its behalf by
a third party, in each case solely for applications within the Field.

                  2.2 Notwithstanding the foregoing, LXR shall have the right to
approve any sublicense granted by Introgen to a third party (where such third
party has a capitalization of less than [*] as determined by Introgen and such
third party in good faith), which approval shall not be unreasonably withheld;
otherwise, LXR shall have no right to approve sublicenses. In addition, in the
event that Introgen grants a sublicense under the Patent Rights and Related
Technology to any party, it agrees to provide LXR a copy of such agreement
(reasonably redacted).

                  2.3 Promptly following the execution of the License Agreement
and for the duration of the License Agreement, to the extent LXR may legally do
so, LXR will provide to Introgen all data, materials (including reasonable
samples of biological materials), reports, analyses and other information in its
possession necessary for Introgen to exercise its rights under the license
granted for use in the Field. Introgen may provide such data, materials and
other information, on a need-to-know basis, to those third parties who require
such data, materials or information in order to (i) obtain regulatory approvals
to manufacture and market Licensed Products for use in the Field, or (ii)
commercialize Licensed Products for use in the Field, under binders of
confidentiality no less stringent than those contained in the Agreement. LXR
shall have the right, without restriction, to use any and all such data,
materials, reports, analyses and other information for uses outside the Field.

                  2.4 Introgen agrees to grant to LXR, without payment of any
consideration, an irrevocable, perpetual, transferable, sublicenseable,
royalty-free, non-exclusive, worldwide license under any Introgen Improvement
solely for purposes of manufacturing, selling, importing and using the "bak"
gene for applications outside of the Field. Notwithstanding the foregoing, if
the License Agreement is terminated (but not upon expiration) pursuant to its
terms, [*].

                  2.5 To the extent that Introgen has the right to do so,
Introgen agrees to grant to LXR an option to obtain an exclusive, transferable,
sublicenseable, worldwide license under any Introgen Improvement solely for
purposes of manufacturing, selling, importing and using the "bak" gene for
applications outside of the Field; provided, however, if the License Agreement
is terminated (but not upon expiration) pursuant to its terms, [*]. After
receipt of notification from Introgen of such an Introgen Improvement, LXR shall
notify Introgen within 60 days whether it desires to exercise the foregoing
option with respect to the particular invention. If LXR so elects the parties
shall negotiate in good faith for a period of 90 days the terms and conditions

LXR LICENSE AGREEMENT

[*]  Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3
<PAGE>   4
of an agreement including such license, including milestone and royalty payments
to Introgen; provided, however, such royalty to Introgen shall not exceed the
royalty rates set forth in the "Royalty" section below and such rates shall be
subject to reduction to the same extent as provided for in the "Royalty" section
below. [*].
                  2.6 Introgen will exercise commercially reasonable efforts to
research, develop, manufacture, obtain all necessary governmental approvals for,
and sell Licensed Products throughout the world, first in the United States and
then in other major markets of the world including but not limited to England,
Japan, Italy, France, Germany and Spain.

         3. ROYALTY AND PAYMENTS

                  3.1 Introgen will pay to LXR the following amounts in United
States dollars (which amounts shall be non-refundable) upon accomplishment of
each of the following milestones with respect to the first Licensed Product for
which such milestone is accomplished:

                  [*]               Upon the first successful completion of
                                    [*] for the first Licensed Product.

                  [*]               Upon the first successful completion of
                                    [*] for the first Licensed Product; and

                  [*]               Upon [*] of the first Licensed Product in
                                    the United States.

[*]
                  3.2 Introgen will be responsible for all costs and expenses of
developing, testing and registering Licensed Products and for obtaining and
maintaining regulatory approvals therefor, and for all costs of manufacturing,
promoting, marketing and selling Licensed Products.

                  3.3 In the case of Patented Products, Introgen will pay to LXR
royalties at the rate of [*] of Net Sales by Introgen, its affiliates and
sublicensees of Patented Products to unaffiliated third parties, such royalties
to be paid quarterly. Such [*] royalty rate shall apply even if the Patented
Product includes the "bak" gene and one or more other products and/or
technologies (including without limitation delivery systems therefor). Such [*]
royalty payment shall continue on a country-by-country basis until last to
expire of any Valid Claim under the Patent Rights in such country.

LXR LICENSE AGREEMENT

[*]  Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       4
<PAGE>   5
                  3.4 In the case of Non-Patented Products, Introgen will pay to
LXR royalties at the rate of [*] of Net Sales of Non-Patented Products by
Introgen, its affiliates and sublicensees to unaffiliated third parties, such
royalties to be paid quarterly. Such [*] royalty rate shall apply even if the
Non-Patented Product includes the "bak" gene and one or more other products
and/or technologies (including without limitation delivery systems therefor).
Such [*] royalty payment for know-how shall continue on a country-by-country
basis until ten (10) years from the first commercial sale of a Non-Patented
Product in a particular country. Notwithstanding the foregoing, if during such
ten (10) year period, a patent application covering the manufacture, formulation
or use of a Non-Patented Product is filed in such country, then the royalty rate
shall increase to [*] from the date such patent application is filed, and such
[*] royalty payment shall continue in such country until the last to expire of
any Valid Claim under the Patent Rights in such country.

                  3.5 In the event a third party claims that the "bak" gene
alone, or its use alone infringes such third party's patent rights, and
Introgen; or an affiliate or sublicensee becomes obligated to make payments of
any kind to such third party solely with respect to such third party's patent
rights covering the "bak" gene or use thereof, provided Introgen's use of the
"bak" gene is within the Field, Introgen may deduct [*] of the amounts owing to
such third party from the royalty payments owing to LXR under the License
Agreement; provided, however, that no royalty payment to be made by Introgen to
LXR under the License Agreement shall be reduced by more than [*] of the royalty
payment that is otherwise due to LXR under the License Agreement.

         4. INTELLECTUAL PROPERTY

                  4.1 LXR will have the right to control prosecution of the
Patent Rights. Introgen shall reimburse LXR for the out-of-pocket fees and
expenses incurred after the execution of the License Agreement for any and all
filing, prosecution and maintenance of patents and patent applications included
within the Patent Rights. LXR agrees to confer with Introgen regarding the
prosecution of patent applications and patents within Patent Rights, and to take
into consideration recommendations made by Introgen with respect to the handling
of such prosecution. If Introgen decides not to proceed with the prosecution of
one or more patents or applications within Patent Rights, any such patent or
application shall be excluded from the scope of Patent Rights, and Introgen's
continuing obligation of with respect to such patent or application shall cease.
If LXR elects not to prosecute any patent application or maintain any patent in
the Patent Rights, or fails to do so, LXR will notify Introgen and Introgen will
have the right to pursue such prosecution or maintenance at Introgen's sole
expense. Introgen shall be permitted to deduct [*] of any reimbursement by
Introgen to LXR under this subsection [*] from any milestone payments made by
Introgen under subsection 3.1 hereof, however, in the event that LXR grants a
license to practice Patent Rights outside of the Field to any third party, or if
LXR itself seeks to commercialize products or processes covered under Patent
Rights outside of the Field, LXR shall refund to Introgen any portion of the [*]
that has not been as of that time deducted from any milestone payment.

                  4.2 LXR agrees to provide Introgen with copies of all patents,
patent applications and

LXR LICENSE AGREEMENT

[*]  Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       5
<PAGE>   6
prosecution files of patents and applications within Patent Rights, and,
further, agrees to provide Introgen in a timely fashion with copies of all
prosecution documents that it receives with respect to patents and applications
within Patent Rights in the future. LXR agrees to consult with Introgen in a
timely fashion with respect to the prosecution of the Patent Rights and to
consider recommendations made by Introgen with respect thereto.

                  4.3 Introgen shall have the first right to enforce the Patent
Rights with respect to infringements within the Field; provided, however if
Introgen fails to bring an action to enforce the Patent Right within 6 months
after LXR has provided Introgen with reasonable evidence of a substantial
infringement, LXR shall have the right to bring such action. In either case the
non-controlling party will cooperate in such action at the other's expense. The
party initiating any such action will keep the other party reasonably informed
of the progress thereof, and such other party will have the right to participate
with counsel of its own choice. All awards from such enforcement actions (after
reimbursing the parties' costs and expenses related thereto) shall be treated as
follows: (i) if Introgen brings such action, Introgen shall [*], and (ii) if LXR
brings such action, LXR shall [*].

                  4.4 If the production, sale or use of any Licensed Product
within the Field results in a claim, suit or proceeding alleging patent
infringement against Introgen, its affiliates or sublicensees, Introgen will
have the exclusive right to defend and control the defense of any such action
using counsel of its own choice at its expense; provided, however, that LXR may
participate in the defense and/or settlement thereof at its own expense with
counsel of its choice. Except as agreed in writing by LXR, Introgen will not
enter into any settlement relating to a Licensed Product, if such settlement
admits the invalidity or unenforceability of any patent within the Patent
Rights. Introgen agrees to keep the LXR reasonably informed of all material
developments in connection with any such action. [*].

                  4.5 Notwithstanding the foregoing, in the event such claim of
infringement does not involve allegations that the manufacture, use or sale of
the "bak" gene infringes a third party patent, then Introgen shall defend,
indemnify and hold harmless LXR and its affiliates and their respective
directors, officers, agents, employees, successors and assigns from and against
such claim and any and all liabilities, damages, losses, costs and expenses
(including without limitation attorney's fees and costs of litigation,
regardless of outcome) arising therefrom, subject to standard indemnification
procedure and provided that LXR shall have the right to participate in any such
action with counsel of its own choosing at its own expense. [*].

LXR LICENSE AGREEMENT

[*]  Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       6
<PAGE>   7

         5. CONFIDENTIALITY.

                  5.1 Confidential Information. Except as provided herein, each
party shall maintain in confidence, and shall not disclose to any third party,
any information, data or materials (whether of a business or technical nature
and in whatever form) disclosed by the other party in writing and marked
"Confidential" or that is disclosed orally and confirmed in writing as
confidential within forty-five (45) days following such disclosure
(collectively, "Confidential Information"). Except as provided for herein, it is
agreed that the furnishing of Confidential Information by one party to the other
party hereunder does not and shall not constitute any grant, option or license
to the receiving party under any patent or other rights now or hereafter held by
the disclosing party with respect to such Confidential Information. Confidential
Information shall not include any information that is: (i) already known to the
receiving party at the time of disclosure hereunder (other than from the other
party hereto) as demonstrated by its written records, (ii) now or hereafter
becomes publicly known other than through acts or omissions of the receiving
party, or anyone to whom the receiving party disclosed such information, (iii)
disclosed to the receiving party by a third party under no obligation of
confidentiality to the disclosing party or any other party, or (iv)
independently developed by the receiving party without reliance on the
Confidential Information of the disclosing party as shown by its written
records.

                  5.2 Permitted Usage. The receiving party may use or disclose
Confidential Information of the disclosing party to the extent necessary to
exercise its rights hereunder or in filing for, prosecuting or maintaining any
proprietary rights (including patents), prosecuting or defending litigation, or
complying with applicable governmental regulations; provided however, if the
receiving party is required by law or a court of competent jurisdiction to make
any public disclosures of Confidential Information of the disclosing party, to
the extent it may legally do so, it will give reasonable advance notice to the
disclosing party of such disclosure and will use its reasonable good faith
efforts, or, at the option of the disclosing party, enable the disclosing party,
to secure confidential treatment of Confidential Information prior to its
disclosure (whether through protective orders or otherwise).

                  5.3 Prohibited Actions. Subject to Section 5.1 above, Introgen
hereby agrees to consult with LXR prior to filing any patent application
containing any claim the subject matter of which contains, is based upon, or is
derived from the Confidential Information of LXR. In addition, the parties agree
to consult with respect to the filing and prosecution of patent applications
claiming inventions that are jointly owned. Moreover, Introgen shall not use
Confidential Information of LXR for any purpose or in any manner which would
constitute a violation of any laws or regulations of the United States.

                  5.4 Injunctive Relief. The parties recognize that any breach
of this Article 5 would irreparably harm the disclosing party, and that the
disclosing party is thereby entitled to equitable relief (including without
limitation, injunctions) with respect to any such breach or potential breach by
the receiving party, in addition to any other remedies.

                  5.5 Retroactive Effect. This Article 5 shall be made
retroactive to March 7, 1998, the date on which the parties commenced their
discussions regarding the subject matter of this Agreement.

LXR LICENSE AGREEMENT                  7
<PAGE>   8

         6. WARRANTIES.

                  6.1 LXR. LXR hereby represents and warrants to Introgen that
as of the Effective Date: (i) LXR has the right to enter into the License
Agreement and grant the rights granted therein; (ii) LXR has not granted and
will not grant during the term of the License Agreement, rights in or to the
Licensed Products or Related Technology that are inconsistent with the rights
granted to Introgen under the License Agreement, (iii) to the best of its
knowledge there are no claims of third parties challenging the right of LXR to
grant to Introgen the rights under the License Agreement and (iv) except for the
Patent Rights, LXR does not own or control any patents or patent applications
the claims of which would dominate any practice of the Patent Rights by Introgen
under the License Agreement.

                  6.2 Introgen. Introgen hereby represents and warrants to LXR
that as of the Effective Date: (i) Introgen has the right to enter into this
Agreement, (ii) to its knowledge, there are no claims of third parties that
would prohibit or restrict Introgen's ability to perform its obligations under
this Agreement, and (iii) Introgen will endeavor to conduct its research,
development, manufacture and sale of Licensed Products in accordance with all
applicable laws and regulations.

                  6.3 Disclaimer of Warranties and Limitation of Liability.
EXCEPT AS PROVIDED IN THIS ARTICLE 7, NEITHER PARTY MAKES ANY WARRANTIES OR
REPRESENTATIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE
SUBJECT MATTER HEREOF INCLUDING, BUT NOT LIMITED TO ANY PATENT, TRADEMARK,
SOFTWARE, NON-PUBLIC OR OTHER DATA OR INFORMATION, OR TANGIBLE RESEARCH PROPERTY
INCLUDING SAMPLES. LXR SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OR
REPRESENTATIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NOTHING
IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN
BY LXR; WITH REGARD TO THE UTILITY OF ANY SAMPLES; THE SCOPE, VALIDITY OR
ENFORCEABILITY OF THE PATENT RIGHTS; THAT ANY PATENT WILL ISSUE BASED UPON ANY
PENDING PATENT APPLICATION INCLUDED IN THE PATENT RIGHTS; OR THAT THE EXERCISE
OF THE PATENT RIGHTS OR USE OF THE RELATED TECHNOLOGY WILL NOT INFRINGE THE
PATENT OR PROPRIETARY RIGHTS OF ANY OTHER THIRD PARTY. TO THE EXTENT SAMPLES ARE
FURNISHED HEREUNDER, LXR MAKES NO REPRESENTATION THAT SUCH SAMPLES OR THE
METHODS USED IN MAKING OR USING SUCH SAMPLES ARE FREE FROM LIABILITY FOR PATENT
INFRINGEMENT. EXCEPT AS EXPRESSLY PROVIDED FOR HEREUNDER, LXR SHALL HAVE NO
LIABILITY OF ANY KIND WHATSOEVER TO INTROGEN RESULTING FROM THE EXERCISE OF
RIGHTS HEREUNDER, WHETHER SUCH LIABILITY ARISES IN CONTRACT, TORT OR STRICT
LIABILITY, WITH THE EXCEPTION OF THE PARTIES' DEFEND, INDEMNIFY AND HOLD
HARMLESS OBLIGATIONS UNDER SECTION 8, IN NO EVENT WILL EITHER PARTY BE LIABLE
FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM
THE LICENSE HEREUNDER (INCLUDING THE USE OF THE PATENT RIGHTS, RELATED
TECHNOLOGY OR SAMPLES), EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES.

LXR LICENSE AGREEMENT                  8
<PAGE>   9

         7. TERM/TERMINATION.

                  7.1 Term. The term of this Agreement shall commence on the
Effective Date and shall continue in full force and effect until expiration of
the later of ten (10) years from the first commercial sale of a Patented Product
in a particular country, or the last to expire of any Valid Claim under the
Patent Rights in such country.

                  7.2 Termination. Introgen shall have the right to terminate
this Agreement for any reason upon written notice to LXR at any time. This
Agreement shall automatically terminate if Introgen commits a material breach or
defaults in the performance of a material obligation hereunder, and fails to
remedy or cure such breach or default within thirty (30) days after being called
upon in writing to do so by LXR.

                  7.3 Effect of Termination. Upon expiration or termination of
this Agreement for any reason, Introgen shall return to LXR and shall cease all
use of all Confidential Information of LXR including without limitation, all
information, data, materials, samples and documents provided by LXR under this
Agreement, except that Introgen may retain one (1) copy of such information,
data and documents in the files of its legal counsel solely for the purposes of
complying with its ongoing confidentiality obligations hereunder.

                  7.4 Survival. Sections 7.3, and Articles 5, 6, 8 and 9 shall
survive the expiration or termination of this Agreement.

         8. INDEMNIFICATION.

                  8.1 Except as otherwise specified in Section 4.5 above,
Introgen shall indemnify, defend and hold harmless LXR, its affiliates, and
their respective directors, officers, employees, agents, successors and assigns
against any liability, damage, loss, cost or expense (including reasonable
attorneys' fees and expenses of litigation, regardless of outcome) incurred by
or imposed upon the indemnitees, or any one of them, in connection with any
third party claims, suits, actions demands or judgments arising out of any acts
or omissions by or on behalf of Introgen pursuant to this Agreement, or any
negligence, misconduct or breach of this Agreement by Introgen or its employees,
agents or contractors; provided that an indemnitee that intends to claim
indemnification under this Section 8 shall: (i) promptly notify Introgen in
writing of such claim, suit or action with respect to which indemnitee intends
to claim such indemnification, (ii) subject to Section 8.4., give Introgen sole
control of the defense and/or settlement thereof, (iii) provide Introgen, at
Introgen's expense, with reasonable assistance and full information with respect
thereto. Notwithstanding the foregoing, Introgen shall have no obligations for
any claim if the indemnitee seeking indemnification makes any admission or
settlement regarding such claim without the prior written consent of Introgen,
which consent shall not be unreasonably withheld.

                  8.2 Exception. The indemnification under Section 8.1 shall not
apply to any liability, damage, loss, cost or expense to the extent attributable
to the gross negligence or intentional misconduct of the indemnitees.

LXR LICENSE AGREEMENT                  9
<PAGE>   10

                  8.3 Attorneys. The indemnifying party agrees, at that party's
sole expense, to provide counsel reasonably acceptable to the indemnitee party
to defend against any actions brought or filed against any indemnitee with
respect to any indemnification obligation herein, whether or not such actions
are rightfully brought. The indemnitee shall have the right to participate with
counsel of its own choosing at its own expense.

         9. MISCELLANEOUS.

                  9.1 Independent Contractors. The relationship of LXR and
Introgen established by this Agreement is that of independent contractors.
Nothing in this Agreement shall be construed to create any other relationship
between LXR and Introgen. Neither party shall have any right, power or authority
to assume, create or incur any expense, liability or obligation, expressed or
implied, on behalf of the other.

                  9.2 Confidential Terms. Except as expressly provided herein,
each party agrees not to disclose any terms of this Agreement to any third party
without the prior written consent of the other party, except as required by
securities or other applicable laws, or such party's accountants, attorneys and
other professional advisors, potential investors and partners, under binders of
confidentiality no less stringent than those contained herein.

                  9.3 Assignment. This Agreement shall not be assignable by
either party to any third party without the prior written consent of the other
party hereto. Notwithstanding the foregoing, either party may assign this
Agreement without the consent of the other party to a party that is an affiliate
of the assigning party at the time of the assignment, or to an entity that
acquires substantially all of the business or assets of such party whether by
merger, acquisition, sale or otherwise, provided that in either case, such
assignee agrees in writing to be bound by the terms and conditions of this
Agreement. Notwithstanding the foregoing, LXR may assign this Agreement without
the consent of Introgen to an entity that acquires substantially all of the
Patent Rights, provided such assignee agrees in writing to be bound by the terms
and conditions of this Agreement. In the event of any such assignment all
references to the assigning party shall be deemed to be references to the
assignee. Any purported assignment in violation of this section shall be null
and void. For the purposes hereof, an "affiliate" of a party shall mean any
corporation or other business entity that controls, is controlled by or under
common control with such party.

                  9.4 Notices. Any notice or other communication required by
this Agreement shall be made in writing and given by prepaid, first class,
certified mail, return receipt requested, and shall be deemed to have been
served on the date received by the addressee at the following address or such
other address as may from time to time be designated by the other party in
writing:

                  If to LXR:       LXR Biotechnology, Inc.
                                   3095 Richmond Parkway, Suite 213
                                   Richmond, CA 94806
                                   Attention: Paul Hastings
                                   Phone: (510) 758-4396
                                   Fax:   (510) 758-4397

LXR LICENSE AGREEMENT                  10
<PAGE>   11

                 If to Introgen:   Introgen Therapeutics, Inc.
                                   301 Congress Avenue, Suite 1850
                                   Austin, Texas 78701
                                   Attn: David Parker
                                   Phone: (512) 708-9310
                                   Fax:   (512) 708-9311

                  9.5 Compliance with Law. Each party shall comply with all
applicable federal, state and local laws and regulations in connection with its
activities pursuant to this Agreement. Each party hereby acknowledges that its
rights and obligations under this Agreement are subject to the laws and
regulations of the United States relating to the export of products and
technical information. Without limitation, each party shall comply with all such
laws and regulations.

                  9.6 Governing Law. This Agreement shall be governed by, and
construed and interpreted in accordance with, the laws of the State of
California, without reference to its or any other jurisdiction's principles of
conflicts of law.

                  9.7 No Waiver. A waiver express or implied, by either LXR or
Introgen of any right under this Agreement or of any failure to perform or
breach hereof by the other party hereto shall not constitute or be deemed to be
a waiver of any other right hereunder or of any other failure to perform or
breach hereof by such other party, whether of a similar or dissimilar nature
thereto.

                  9.8 Severability. If any provision of this Agreement shall be
found by a court to be void, invalid or unenforceable, the same shall be
conformed to comply with applicable law or stricken if not so conformable, so as
not to affect the validity or enforceability of the remainder of this Agreement.

                  9.9 Entire Agreement. This Agreement constitutes the entire
understanding of the agreement between the parties with respect to the subject
matter hereof and supersede any and all prior negotiations, representations,
agreements and understandings, written or oral, that the parties may have
reached with respect to the subject matter hereof. No agreements altering or
supplementing the terms hereof may be made except by means of a written document
signed by the duly authorized representatives of each of the parties hereto.

                  9.10 Counterparts. This Agreement shall be executed in two
counterparts, each of which shall be deemed an original, but both of which
together shall constitute one and the same instrument.

LXR LICENSE AGREEMENT                  11
<PAGE>   12

         IN WITNESS WHEREOF, the parties have caused their duly authorized
representatives to execute this Agreement.

LXR BIOTECHNOLOGY, INC.                      INTROGEN THERAPEUTICS, INC.

By: /s/ PAUL J. HASTINGS                     By: /s/ DAVID PARKER
   ------------------------------               -------------------------------

Name:   Paul J. Hastings                     Name:   DAVID PARKER
     ----------------------------                 -----------------------------

Title:  Director                             Title:  V.P. Intellectual Property
      ---------------------------                  ----------------------------

LXR LICENSE AGREEMENT                  12<PAGE>   1
                                                                   EXHIBIT 10.34

                    [FINOVA FINANCIAL INNOVATORS LETTERHEAD]

MASTER LEASE No. S7430, Dated August 4, 1999

FINOVA Capital Corporation ("we","us" or "FINOVA") agrees to lease to Introgen
Therapeutics, Inc. ("you" or "Lessee") and you agree to lease from us, the
Equipment described in any schedule to this Lease (a "Schedule"). The Equipment
also includes any replacement parts, repairs, additions and accessories that you
may add to the Equipment. We may treat any Schedule as a separate lease
containing all of the provisions of this Lease.

     1. PURCHASING AND INSTALLING THE EQUIPMENT

     We will purchase the Equipment from you or from the Supplier you chose. The
     Supplier will deliver  the Equipment to you at your expense. You will
     properly install the Equipment at your expense at the location(s)
     indicated in the Schedule.

     2. TERM

     The Term of each Schedule begins on the date payment is made by Lessor to
     Supplier or Lessee for the Equipment on such Schedule, or later date that
     you and  we agree to in writing on the Certificate of Inspection and
     Acceptance.

     o   The Term continues until you fully perform all of your obligations
         under this Lease and the Schedule.

     o   If the Equipment is not delivered, installed and accepted by you by the
         date indicated in the Schedule, we may terminate this Lease and the
         Schedule as to the Equipment that was not delivered, installed and
         accepted by giving you 10 days written notice of termination. Any
         advance rental payments you may have paid us is nonrefundable, even if
         the Term never starts or if we rightfully terminate this Lease or the
         Schedule.

     o   Before we make any progress payment or final payment for the Equipment
         on any Schedule, we require the following:

     o   That no payment is past due to us under any lease, loan or other
         financial arrangement that you or any other guarantor have with us.

     o   That you are complying with all the terms of this Lease.

     o   That we have received all the documents we requested, including the
         signed Schedule and Delivery and Acceptance Certificate.

     o   That there has been no material adverse change in your financial
         condition, business, operations or prospects, or that of any guarantor,
         from the condition that you disclosed to us in your application for
         credit.

     3.  RENT

     o   The rent is indicated on the Schedule. The rent is payable periodically
         in advance from time to time (for example, monthly). You agree that
         you owe us the total of all these rent payments over the Term of the
         Schedule.

     o   The first rent payment is due at the beginning of the Term or at a
         later date that we agree to in writing. Subsequent rent payments are
         due on the same day of each successive period until you pay us in full
         all of the rent and any other charges or expenses you owe us.

     o   If the first rent payment is due later than the beginning of the Term,
         you will also pay us interim rent on the first rent payment date. The
         interim rent will be for the period from the beginning of the Term
         until the date that the first rent payment is due. Interim rent will be
         calculated at the same rate as the regular rent
<PAGE>   2

         payment, but on a daily basis for the number of days for which interim
         rent is due.

     o   YOUR OBLIGATION TO PAY US ALL RENT IS ABSOLUTE AND UNCONDITIONAL. YOU
         ARE NOT EXCUSED FROM PAYING THE RENT, IN FULL, FOR ANY REASON. YOU
         AGREE THAT YOU HAVE NO DEFENSE FOR FAILURE TO PAY THE RENT AND YOU WILL
         NOT MAKE ANY COUNTERCLAIMS OR SETOFFS TO AVOID PAYING THE RENT.

     4.  NON-CANCELABLE LEASE. YOU AGREE THAT YOU MAY NOT CANCEL OR TERMINATE
         THIS LEASE OR ANY SCHEDULE.

     5.  PROTECTION OF OUR INTEREST IN THE EQUIPMENT; FEES.

     o   The Equipment is our property. It will remain our property. You will
         not own the Equipment unless the Schedule gives you an option to
         purchase the Equipment and you have exercised that option and paid us
         in full for the Equipment and any other amounts you may owe us. If we
         request, you will put labels stating "PROPERTY OF FINOVA" on the
         Equipment where they are clearly visible.

     o   You give us permission to add to this Lease or any Schedule the serial
         numbers and other information about the Equipment.

     o   While this Lease is intended to be a lease (and not a loan), you grant
         us a security interest in the Equipment to protect our interest in the
         Equipment if this Lease is later determined to be a security agreement.
         You give us permission to file this Lease or a Uniform Commercial Code
         financing statement, at your expense, in order to perfect this security
         interest. You also give us permission to sign your name on the Uniform
         Commercial Code financing statements where this is permitted by law.

     o   You will pay our reasonable cost to do searches for other filings or
         judgments against you or your affiliates. You will also pay any
         ordinary filing, recording or stamp fees or taxes resulting from filing
         this Lease or a Uniform Commercial Code financing statement. You will
         also pay our reasonable fees from time to time that we pay to third
         parties for documentation, administration and Termination of this
         Lease.

     o   At your expense, you will defend our ownership rights in the Equipment
         against, and keep the Equipment free of, any legal process, liens,
         security interests, attachments, levies and executions. You will give
         us immediate written notice of any legal process, liens, attachments,
         levies or executions, and you will indemnify us against any loss that
         results to us from these causes.

     o   You will notify us at least 15 days before you change the address of
         your principal executive office.

     o   You will promptly sign and return additional documents that we may
         reasonably request in order to protect our interest in the Equipment.

     o   The Equipment is personal property and will remain personal property.
         You will not incorporate it into real estate and will not do
         anything that will cause the Equipment to become part of real estate or
         a fixture.

     6.  CARE, USE, LOCATION AND ALTERATION OF THE EQUIPMENT.

     o   You will make sure that the Equipment is maintained in good operating
         condition, and that it is serviced, repaired and overhauled when this
         is necessary to keep the Equipment in good operating condition. All
         maintenance must be done according to the Supplier's or Manufacturer's
         requirements or recommendations. All maintenance must also comply with
         any legal or regulatory requirements.

     o   You will maintain service logs for the Equipment and permit us to
         inspect the Equipment, the service logs and service reports. You give
         us permission to make copies of the service logs and service reports.

     o   We will give you five business days prior notice if we, or our agent,
         want to inspect the Equipment or the service logs or service reports.
         We may inspect it during regular business hours. You will pay our
         reasonable travel including airline travel at coach class rates only,
         meals and

                                       2
<PAGE>   3

     lodging costs to inspect the Equipment, but only for one inspection per
     year. If we find during an inspection that you are not complying with this
     Lease, you will pay our reasonable travel including airline travel at coach
     class rates only, meals and lodging costs, our salary costs, and the costs
     and fees of our agents for reinspection. You will promptly cure any
     problems with the Equipment that are discovered during our inspection.

o    You will use the Equipment only for business purposes. You will obey
     all legal and regulatory requirements in your use of the Equipment.

o    You will make all additions, modifications and improvements to the
     Equipment that are required by law or governmental regulation. Otherwise,
     you will not alter the Equipment without our written permission. You will
     replace all worn, lost, stolen or destroyed parts of the Equipment with
     replacement parts that are as good or better than the original parts. The
     new parts will become our property upon replacement.

o    You will not remove the Equipment from the location indicated in the
     Schedule without our written permission.

7. RETURN OF EQUIPMENT. UNLESS OTHERWISE STATED IN THE SCHEDULE:

o    You must give us written notice at least 120 days before the end of the
     Term if you want to purchase the equipment from us (assuming the Schedule
     provides you with an option to purchase the Equipment).

o    You must give us written notice at least 120 days before the end of the
     Term if you want to return the Equipment to us.

o    If you do not give us written notice of at least 120 days before the end of
     the Term either that you want to purchase or that you want to return the
     Equipment, you will continue to rent the Equipment and this Lease and the
     Schedule will be automatically extended until 120 days after we receive
     your notice. The rent will be the fair market rental value of this
     Equipment, as reasonably determined by us. Unless we notify you otherwise,
     the fair market rental value will not exceed the rent then being charged
     under this Lease and the Schedule.

o    If you do give us 120 days written notice that you want to purchase the
     Equipment but you do not pay us the purchase price, you will continue to
     rent the Equipment. The rent will be the fair market rental value of the
     Equipment, as reasonably determined by us. You will continue to pay us this
     rent until you have paid the purchase price for the Equipment. The rent
     payments will not be credited to the purchase price.

o    If you do give us 120 days written notice that you want to return the
     Equipment to us, but you do not return the Equipment in compliance with the
     return conditions contained in the next paragraph, you will continue to
     rent the Equipment. The rent will be the fair market rental value of the
     Equipment, as reasonably determined by us. You will continue to pay us this
     rent until you have returned the Equipment to us in compliance with these
     return conditions.

o    Return conditions: - You will return the Equipment, freight and insurance
     prepaid by you, to us at a location we request in the United States of
     America. It will be returned in good operating condition, as required by
     section 6 above. The Equipment will not be subject to any liens when it is
     returned.

     *    You will pack or crate the Equipment for shipping in the original
          containers, or comparable ones. You will do this carefully and follow
          all recommendations of the Supplier and the Manufacturer as to packing
          or crating.

     *    You will also return to us the plans, specifications, operating
          manuals, software documentation, discs, warranties and other documents
          furnished by the Manufacturer or Supplier. You will also return to us
          all service logs and service reports, as well as all written materials
          that you may have concerning the maintenance and operation of the
          Equipment.

     *    At our request, you will provide us with up to 60 days free storage of
          the Equipment at your location, and will let us (or our agent) have
          access to the Equipment in order to inspect it and sell it.

                                       3
<PAGE>   4

         *        You will pay us what it costs us to repair the Equipment if
                  you do not return it in the required condition.

8.   RISK OF LOSS

o        You have the complete risk of loss or damage to the Equipment. Loss or
         damage to the Equipment will not relieve you of your obligation to pay
         rent.

o        If any Equipment is lost or damaged, you have two choices (although if
         you are in default under this Lease, we and not you will have the two
         options). The choices are:

(1)      Repair or replace the damaged or lost Equipment so that, once again, we
         own Equipment in good operating condition and have clear title to it.

(2)      Pay us the present value (as of the date of payment) of the remaining
         rent payments and our residual interest in the Equipment. We will
         calculate the present value using a discount rate of five (5%) percent
         per year. Once you have paid us this amount and any other amount that
         you may owe us, you (or your insurer) may keep the Equipment for
         salvage purposes, on an "AS IS, WHERE IS" basis.

9.   INSURANCE

o        Until you have properly returned the Equipment to us, you will keep it
         insured. The amount of the insurance, the coverage, and the insurance
         company must be acceptable to us all of which we will determine in a
         reasonable manner.

o        If you do not provide us with written evidence of insurance that is
         acceptable to us, we may buy the insurance ourselves, at your expense.
         You will promptly pay us the cost of this insurance. We have no
         obligation to purchase any insurance. Any insurance that we purchase
         will be our insurance, and not yours, and may insure the Equipment
         beyond the end of the Term.

o        Insurance proceeds may be used to repair or replace damaged or lost
         Equipment or to pay us the present value of the rent and our residual
         interest in the Equipment. (See section 8, "Risk of Loss", above.)

o        In the event of default as provided in Section 12, you appoint us as
         your "attorney-in-fact" to make claims under the insurance policies, to
         receive payments under the insurance policies, and to endorse your name
         on all documents, checks or drafts relating to insurance claims for
         Equipment.

10.  TAXES

o        You will pay all sales, use, excise, stamp, documentary and ad valorum
         taxes, license and registration fees, assessments, fines, penalties and
         similar charges imposed on the ownership, possession, use or lease of
         the Equipment.

o        You will pay all taxes (other than our federal or state net income or
         Texas franchise taxes) imposed on you or on us or the rent payments.

o        You will reimburse us for any of these taxes that we pay or advance.

Unless we notify you otherwise and FINOVA is notified by the taxing jurisdiction
that property needs to be reported, we will timely file and pay for any personal
property taxes on the Equipment. You will reimburse us for the full amount of
these taxes, without regard to early payment discount by no later than the due
date of actual taxes (January 31). We may estimate the amount of these taxes in
advance and bill you in advance for these taxes if it is not likely that the
actual will be paid prior to the contract termination.

11.  INDEMNITY

o        You will indemnify us, defend us and hold us harmless unless we are
         negligent. This applies to any and all claims, expenses and attorney's
         fees concerning or arising from the Equipment, this Lease, or any
         Schedule. It includes any claims concerning the manufacture, selection,
         delivery, possession, use, operation or return of the Equipment.

o        This obligation of yours to indemnify us continues even after the Term
         is over.

12.  DEFAULT

You are in default if any of the following happens:

                                       4
<PAGE>   5

o    You do not pay us, when it is due, any rent payment or other payment that
     you owe us under this Lease, any Schedule, or any other lease, loan or
     other financial arrangement that you have with us.

o    Any of the financial information that you give us is materially not true or
     materially incomplete, or you fail to tell us anything that would make the
     financial information materially misleading.

o    You do something you are not permitted to do, or you fail to do anything
     that is required of you, under this Lease, any Schedule or any other lease,
     loan or other financial arrangement that you have with us which is not
     cured within 30 days.

o    An event of default occurs for any other lease, loan or obligation of yours
     (or any guarantor) that exceeds $50,000.

o    You or any guarantor file bankruptcy, or involuntary bankruptcy is filed
     against you or any guarantor and is not dismissed within 60 days.

o    You or any guarantor are subject to any other insolvency proceeding other
     than bankruptcy (for example, a receivership action or an assignment for
     benefit of creditors) and such proceeding that is involuntary is not
     dismissed within 60 days.

o    Without our permission, you or any guarantor sell all or a substantial part
     of its assets, merge or consolidate, or a majority of your voting stock
     or interests (or any guarantor's voting stock or interests) is transferred
     except for the sale of newly issued securities to investors or the sale of
     newly issued or existing securities to Rhone-Poulenc Rorer
     Pharmaceuticals, Inc. or its affiliates.

o    There is a material adverse change in your financial condition, business,
     operations or prospects, or that of any guarantor, from the condition that
     you disclosed to us in your application for credit.

13. REMEDIES, DEFAULT INTEREST, LATE FEES

If you are in default we may exercise one or more of our "remedies." Each of our
remedies is independent. We may exercise any of our remedies, all of our
remedies or none of our remedies. We may exercise them in any order we choose.
Our exercise of any remedy will not prevent us from exercising any other remedy
or be an "election of remedies." If we do not exercise a remedy, or if we delay
in exercising a remedy, this does not mean that we are forgiving your default or
that we are giving up our right to exercise the remedy. Our remedies allow us to
do one or more of the following:

o    Require you to immediately pay us all unpaid rent for the entire Term for
     any or all Schedules discounted to present value using a rate of 5% per
     year.

o    Require you to immediately pay us all unpaid amounts that you are required
     to pay us for the entire Term of any other leases, loans or other financial
     arrangements that you have with us discounted to present value using a
     rate of 5% per year.

o    Sue you for all rent and other amounts you owe us plus the greater of (1)
     the actual residual value of the Equipment or (2) the residual value we
     assumed when we leased it to you. Future rent and residual value will be
     discounted to present value using a discount rate of five (5%) percent per
     year.

o    Require you at your expense to assemble the Equipment at a location we
     request in the United States of America.

o    Remove and repossess the Equipment from where it is located, without demand
     or notice, or make the Equipment inoperable all to the extent allowed by
     law and to the extent such action does not breach Lessee's standard
     security policies and procedures. We have your permission to remove any
     physical obstructions to removal of the Equipment and we may also
     disconnect and separate all Equipment from other property provided such
     action does not unreasonably disrupt Lessee's activities or damage or
     disrupt the operation of facilities or equipment not subject to the Lease.
     No court order, court hearing or "legal process" will be required for us to
     repossess the Equipment. You will not be entitled to any damages resulting
     from removal or repossession of the Equipment.

                                       5
<PAGE>   6
         We may use, ship, store, repair or lease any Equipment that we
         repossess. We may sell any repossessed Equipment at private or public
         sale. You give us permission to show the Equipment to buyers at your
         location free of charge during normal business hours upon five business
         days advance notice. If we do this, we do not have to remove the
         Equipment from your location. If we repossess the Equipment and sell
         it, we will give you credit for the net sale price, after subtracting
         our costs of repossessing and selling the Equipment. If we rent the
         Equipment to somebody else, we will give you credit for the net rent
         received, after subtracting our costs of repossessing and renting the
         Equipment, but the credit will be discounted to present value using the
         discount rate that we used in calculating your rental payment under the
         Schedule for the Equipment. The credit will be applied against what you
         owe us under this Lease, the Schedules and any other leases, loans or
         other financial arrangements that you have with us. If the credit
         exceeds the amount you owe under this Lease, the Schedules and any
         other leases, loans or other financial arrangements that you have with
         us, we will refund the amount of the excess to you.

o        You will also pay us the following:

o        All our expenses of enforcing our remedies. This includes all our
         expenses to repossess, store, ship, repair and sell the Equipment.

o        Our reasonable attorney's fees and expenses.

o        Default interest on everything you owe us from the date of your default
         to the date on which we are paid in full. The "default interest rate"
         will be one and one-half (1.5%) percent per month. If this interest
         rate exceeds the highest legal interest rate, you will only be required
         to pay us default interest at the highest legal interest rate.

You realize that the damages we could suffer as a result of your default are
very uncertain. You also realize that the value of an unexpired lease Term is
difficult or impossible to calculate. This is why we have agreed with you in
advance on the discount rates and default interest rate to be used in
calculating the payments you will owe us if you default. You agree that, for
these reasons, the payments you will owe us if you default are "agreed" or
"liquidated" damages. You understand that these payments are not "penalties" or
"forfeitures."

You will pay us a late fee whenever you pay any amount that you owe us more
than ten (10) days after it is due. You will pay the late fee within one month
after the late payment was originally due. The late fee will be ten (10%)
percent of the late payment. If this exceeds the highest legal amount we can
charge you; you will only be required to pay the highest legal amount. The late
fee is intended to reimburse us for our collection costs that are caused by late
payment. It is charged in addition to all other amounts you are required to
pay us, including default interest.

14. PERFORMING YOUR OBLIGATIONS IF YOU DO NOT

If you do not perform one or more of your obligations under this Lease or a
Schedule, we may perform it for you. We will notify you in writing at least ten
(10) days before we do this. We do not have to perform any of your obligations
for you. If we do choose to perform them, you will pay us all of our expenses to
perform the obligations. You will also reimburse us for any money that we
advance to perform your obligations, together with interest at the default
interest rate on that amount. This will be additional "rent" that you will owe
us and you will pay it at the same time your next rent payment is due.

15. ASSIGNMENT

WE MAY ASSIGN THIS LEASE OR ANY SCHEDULE OR ANY RENT PAYMENTS WITHOUT YOUR
PERMISSION.

WE MAY GRANT A SECURITY INTEREST IN THE EQUIPMENT WITHOUT YOUR PERMISSION.

THE PERSON TO WHOM WE ASSIGN IS CALLED THE "ASSIGNEE". THE ASSIGNEE WILL NOT
HAVE ANY OF OUR OBLIGATIONS UNDER THIS LEASE. YOU WILL NOT BE ABLE TO RAISE ANY
DEFENSE, COUNTERCLAIM OR OFFSET AGAINST THE ASSIGNEE.

AFTER ASSIGNMENT YOU MAY "QUIETLY ENJOY" THE USE OF THE EQUIPMENT SO LONG AS YOU
ARE NOT IN DEFAULT.

                                       6
<PAGE>   7

UNLESS YOU RECEIVE OUR WRITTEN PERMISSION, YOU MAY NOT ASSIGN OR TRANSFER YOUR
RIGHTS UNDER THIS LEASE OR ANY SCHEDULE. YOU ALSO ARE NOT ALLOWED TO SUBLET THE
EQUIPMENT OR LET ANYBODY ELSE USE IT UNLESS WE GIVE YOU OUR WRITTEN PERMISSION.

16. UNIFORM COMMERCIAL CODE DISCLAIMERS OF WARRANTIES AND WAIVERS

WE DID NOT MANUFACTURE OR SUPPLY THE EQUIPMENT. WE ARE NOT A DEALER IN THE
EQUIPMENT. INSTEAD, YOU CHOSE THE EQUIPMENT.

WE DO NOT MAKE ANY WARRANTY AS TO THE EQUIPMENT. WE DO NOT MAKE ANY WARRANTY AS
TO "MERCHANTABILITY" OR "SUITABILITY" OR "FITNESS FOR A PARTICULAR PURPOSE" OR
"NONINFRINGEMENT" OF ANY PATENT, COPYRIGHT OR OTHER INTELLECTUAL PROPERTY RIGHT.

WE WILL NOT BE RESPONSIBLE FOR ANY LOSS, DAMAGE, OR INJURY TO YOU OR ANYBODY
ELSE AS A RESULT OF ANY DEFECTS, HIDDEN OR OTHERWISE, IN THE EQUIPMENT UNDER
"STRICT LIABILITY" LAWS OR ANY OTHER LAWS.

WE WILL NOT BE RESPONSIBLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES,
LOSS OF PROFITS OR GOODWILL.

WE MAKE NO WARRANTY AS TO THE TREATMENT OF THIS LEASE FOR TAX OR ACCOUNTING
PURPOSES.

If the Equipment is unsatisfactory, you will continue to pay us all rent and
other amounts you are required to pay us. You must seek repair or replacement of
the Equipment solely from the Manufacturer or Supplier and not from us. You
may use our rights under any Manufacturer or Supplier warranties on the
Equipment to get it repaired or replaced. Neither the Manufacturer nor the
Supplier is our "agent," so they cannot speak for us and they are not allowed to
make any changes in this Lease or any Schedule, or give up any of our rights.

17. UNIFORM COMMERCIAL CODE ARTICLE 2A PROVISIONS

This Lease is a "Finance Lease" under Article 2A of the Uniform Commercial
Code. You agree that (a) we have advised you of the identity of the Supplier,
(b) you may have rights under the "supply contract" under which we are
purchasing the Equipment from the Supplier and (c) you may contact the Supplier
for a description of these rights.

YOU WAIVE ANY AND ALL OF YOUR RIGHTS AND REMEDIES UNDER ARTICLE 2A OF THE
UNIFORM COMMERCIAL CODE, INCLUDING SECTION 2A-508 THROUGH 2A-522 OF THE UNIFORM
COMMERCIAL CODE.

18. ACCEPTANCE BY FINOVA, GOVERNING LAW, JURISDICTION, VENUE, SERVICE OF
PROCESS, WAIVER OF JURY TRIAL.

THIS LEASE WILL ONLY BE BINDING WHEN WE HAVE ACCEPTED IT IN WRITING.

THIS LEASE IS GOVERNED BY THE LAWS OF THE STATE OF ARIZONA, THE STATE IN WHICH
OUR OFFICE IS LOCATED IN WHICH FINAL APPROVAL OF THE TERMS AND CONDITIONS OF
THIS LEASE OCCURRED AND FROM WHICH PAYMENT FOR THE EQUIPMENT WILL BE ORDERED
HOWEVER, IF THIS LEASE IS UNENFORCEABLE UNDER ARIZONA LAW, IT WILL INSTEAD BE
GOVERNED BY THE LAWS OF THE STATE IN WHICH THE EQUIPMENT IS LOCATED.

YOU MAY ONLY SUE US IN A FEDERAL OR STATE COURT THAT IS LOCATED IN MARICOPA
COUNTY, ARIZONA. THIS APPLIES TO ALL LAWSUITS UNDER ALL LEGAL THEORIES,
INCLUDING CONTRACT, TORT AND STRICT LIABILITY. YOU CONSENT TO THE PERSONAL
JURISDICTION OF THESE ARIZONA COURTS. YOU WILL NOT CLAIM THAT MARICOPA COUNTY,
ARIZONA, IS AN "INCONVENIENT FORUM" OR THAT IT IS NOT A PROPER "VENUE."

                                       7
<PAGE>   8
WE MAY SUE YOU IN ANY COURT THAT HAS JURISDICTION. WE MAY SERVE YOU WITH PROCESS
IN A LAWSUIT BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO YOUR ADDRESS
INDICATED AFTER YOUR SIGNATURE BELOW.

YOU AND WE EACH WAIVE ANY RIGHT YOU OR WE MAY HAVE TO A JURY TRIAL IN ANY
LAWSUIT BETWEEN YOU AND US.

19. INFORMATION SUPPLIED BY YOU AND ANY GUARANTOR

o    All financial information and other information that you or any guarantor
     have given us is true and complete in all material respects. You or any
     guarantor have not failed to tell us anything that would make the financial
     information materially misleading. There has been no material adverse
     change in you financial condition, business, operations or prospects, or
     the financial condition of any guarantor, from the financial condition that
     you disclosed to us in your application for credit.

o    You have supplied us with information about the Equipment. You promise to
     us that the amount we are paying for the Equipment is no more than the fair
     and usual price for this kind of Equipment, taking into account any
     discounts, rebates and allowances that you or any affiliate of yours may
     have been given for the Equipment.

o    During the Term you will promptly give copies of any filings you make with
     the Securities and Exchange Commission (SEC). You and any guarantor will
     also provide us with the following financial statements:

o    Quarterly balance sheet and statements of earnings and cash flow - within
     45 days after the end of your first three fiscal quarters in each fiscal
     year. These will be certified by your chief financial officer and
     accompanied by a certificate of your chief financial officer stating that
     no default exists, or, if he or she cannot certify this because a default
     does exist, he or she must specify in reasonable detail the nature of the
     default.

o    Annual balance sheet and statements of earnings and cash flow - within 90
     days after the end of each fiscal year. These will be audited by
     independent auditors acceptable to us (with any of the auditors commonly
     referred to as the Big Five deemed to be acceptable in advance) and will be
     accompanied by a certificate executed by your chief financial officer
     stating that you have complied with all covenants contained in the Lease
     and that there are no events of default thereunder ("the Compliance
     Certificate"). Their audit report must be unqualified.

These financial statements will be prepared according to generally accepted
accounting principles, consistently applied.

All financial statements and SEC filings that you or any guarantor provide us
will be true and complete in all material respects. They will not fail to tell
us anything that would make them materially misleading.

20. NOTICES

We may give you written notice in person, by mail, by overnight delivery
service, or by fax. Notice will be sent to your address below your signature.
Mail notice will be effective three (3) days after we mail it with prepaid
postage to the right address. Overnight delivery notice requires a receipt and
tracking number. Fax notice requires a receipt from the sending machine showing
that it has been sent to your fax number and received.

You may give us notice the same way that we may give you notice.

21. GENERAL

This Lease benefits our successors and assigns. This Lease benefits only those
successors and assigns of yours that we have approved in writing.

This Lease binds your successors and assigns. This Lease binds only those
successors and assigns of ours that clearly assume our obligations in writing.

TIME IS OF THE ESSENCE OF THIS LEASE.

This Lease and all of the Schedules is the entire agreement between you and us
concerning the Equipment.

                                       8
<PAGE>   9
Only an employee of FINOVA who is authorized by corporate resolution or policy
may modify or amend this Lease or any Schedule on our behalf, and this must be
in writing. Only he or she may give up any of our rights, and this must be in
writing. If more than one person is the Lessee under this Lease, then each of
you is jointly and severally liable for your obligations under this Lease.

This Lease is only for your benefit and for our benefit, as well as our
successors and assigns. It is not intended to benefit any other person.

If any provision in this Lease is unenforceable, then that provision must be
deleted. Only unenforceable provisions are to be deleted. The rest of the lease
will remain as written.

22. YEAR 2000

You represent, warrant and agree to take all action necessary including but
not limited to due inquiry and due diligence to assure that there will be no
material adverse change to your business by reason of the advent of the year
2000, including without limitation that all computer based systems, embedded
microchips and other processing capabilities effectively recognize and process
all dates before and after December 31, 1999 ("Y2K Compliant"). At our request,
you will provide to us assurance reasonably acceptable to us that your
computer-based systems, embedded microchips and other processing capabilities
are Y2K Compliant.

23. REPRESENTATIONS AND WARRANTIES

You represent and warrant to us as follows:

o    You have complied with "environmental laws" and will continue to comply
     with all "environmental laws." No "hazardous substances" are used,
     generated, treated, stored of disposed of by you or at your properties
     except in compliance with all environmental laws. "Environmental laws" mean
     all federal, state or local environmental laws and regulations, including
     the following laws: CERCLA, RCRA, Hazardous Materials Transport Act and The
     Federal Water Pollution Control Act. "Hazardous substances" means all
     hazardous or toxic wastes, materials or substances, as defined in the
     environmental laws, as well as oil, flammable substances, asbestos that is
     or could become friable, urea formaldehyde insulation, polychlorinated
     biphenyls and radon gas.

25. PUBLICITY

We make press releases and publish a tombstone announcing this transaction and
its total amount. You may not publicize this transaction in any way without our
prior written consent.

LESSOR:                                LESSEE:
FINOVA CAPITAL CORPORATION             INTROGEN THERAPEUTICS, INC.
10 Waterside Drive                     301 CONGRESS AVENUE
Farmington, Connecticut 06032-3065     AUSTIN, TX 78701

BY: /s/ LINDA A. MOSCHITTO             BY: /s/ JAMES W. ALBRECHT, JR.
   -------------------------------        ---------------------------------

PRINTED NAME: Linda A. Moschitto       PRINTED NAME: James W. Albrecht, Jr.
             ---------------------                  -----------------------

TITLE: Director-Contract               TITLE: Chief Financial Officer
       Administration                         ------------------------------
      ----------------------------

FAX NUMBER: (860)676-1814              Taxpayer ID# 74-2704230
           -----------------------                 ------------------------

DATE ACCEPTED: October 15, 1999        FAX NUMBER: 512-708-9311
              --------------------                -------------------------

                                       DATED: 8-31-99
                                             ------------------------------

STATE OF TEXAS
         ----------
COUNTY OF TRAVIS
          ---------

                                       9
<PAGE>   10
         I acknowledge that James W. Albrecht, Jr., who stated that he is Chief
Financial Officer of the Lessee named above, signed this Master Lease Agreement
in my presence today: September 3, 1999. He acknowledged to me that his
signature on this Master Lease Agreement was authorized by a valid resolution or
other valid authorization from Lessee's board of directors or other governing
body.

                                       /s/ JANIE W. PEPPARD
                                       --------------------
                                       Notary Public

[SEAL]

                                       10
<PAGE>   11

                               LANDLORD'S WAIVER

This Landlord's waiver is made by the person identified below ("you" or
"Landlord") for FINOVA Capital Corporation ("we," "us" or "FINOVA").

You are the owner of real property located at 2250 and 2252 Holcombe Blvd.,
Houston, Texas 77030. You have entered into a lease for all or part of this
property (the "Premises") with Introgen Therapeutics, Inc. (the "Tenant").

We will be leasing to Tenant personal property, which may be machinery,
equipment, furniture or fixtures. This personal property may be leased now or
in the future. We may be filing Uniform Commercial Code financing statements to
protect our interest in this personal property, as well as in any proceeds from
the property. This personal property and its proceeds are referred to as the
"Equipment." The Equipment will be located at the Premises.

We would not lease the Equipment to Tenant without this Landlord's Waiver.
You are benefiting from our leasing the Equipment to Tenant because the
Equipment will be used in Tenant's business. Revenues from Tenant's business
can be used by Tenant to pay you rent for the Premises. You intend to be legally
bound by this Landlord's Waiver.

1. WAIVER.

You acknowledge that you do not own the Equipment. You have no right or interest
in the Equipment. You waive any right under law to any lien on the Equipment.
You waive any right you may have under law or under your lease with Tenant to
levy on the Equipment or distrain the Equipment. You waive any right to make any
claim with respect to the Equipment.

2. PERSONAL PROPERTY.

The Equipment will remain personal property, even if it is attached to your real
estate.

3. REMOVAL OR SALE BY FINOVA

We may remove the Equipment from the Premises. You will not prevent or hinder us
from doing this. We will have no liability to you for this except for the cost
to repair damage actually caused by us to the Premises by removal. If you have
not re-let the Premises to somebody other than Tenant, we may sell the
Equipment from the Premises without having to pay rent.

4. SUCCESSORS AND ASSIGNS.

This Landlord's Waiver is binding upon and benefits your successors and assigns
(including any of your heirs or personal representatives) and our successors and
assigns.

Landlord:  TMX REALTY, INC.              ACCEPTED AND AGREED TO:
          ----------------------         FINOVA CAPITAL CORPORATION

                                         By:    /s/ LINDA A. MOSCHITTO
By:    /s/ DAVID ENLOE                          --------------------------------
    -----------------------------        Name:  Linda A. Moschitto
Name:  DAVID ENLOE                              --------------------------------
      ---------------------------        Title: Director-Contract Administration
Title: PRESIDENT, TMX REALTY, INC.              --------------------------------
      ---------------------------        Date:  October 15, 1999
Date:  9/22/99                                 --------------------------------
      ---------------------------

<PAGE>   12

                               LANDLORD'S WAIVER

This Landlord's waiver is made by the person identified below ("you" or
"Landlord") for FINOVA Capital Corporation ("we","us" or "FINOVA").

You are the owner of real property located at 8014 El Rio, Houston, Texas 77054.
You have entered into a lease for all or part of this property (the "Premises")
with Introgen Therapeutics, Inc. (the "Tenant").

We will be leasing to Tenant personal property, which may be machinery,
equipment, furniture, or fixtures. This personal property may be leased now or
in the future. We may be filing Uniform Commercial Code financing statements to
protect our interest in this personal property, as well as in any proceeds from
the property. This personal property and its proceeds are referred to as the
"Equipment." The Equipment will be located at the Premises.

We would not lease the Equipment to Tenant without this Landlord's Waiver.
You are benefiting from our leasing the Equipment to the Tenant because the
Equipment will be used in Tenant's business. Revenues from the Tenant's business
can be used by Tenant to pay you rent for the Premises. You intend to be legally
bound by this Landlord's Waiver.

1. WAIVER.

You acknowledge that you do not own the Equipment. You have no right or interest
in the Equipment. You waive any right under law to any lien on the Equipment.
You waive any right you may have under law or under you lease with Tenant to
levy on the Equipment or distrain the Equipment. You waive any right to make any
claim with respect to the Equipment.

2. PERSONAL PROPERTY.

The Equipment will remain personal property, even if it is attached to your real
estate.

3. REMOVAL OR SALE BY FINOVA.

We may remove the Equipment from the Premises. You will not prevent or hinder us
from doing this. We will have no liability to you for this except for the cost
to repair damage actually caused by us to the Premises by removal. If you have
not re-let the Premises to somebody other than Tenant, we may sell the
Equipment from the Premises without having to pay rent.

4. SUCCESSORS AND ASSIGNS.

This Landlord's Waiver is binding upon and benefits your successors and assigns
(including any of your heirs or personal representatives) and our successors and
assigns.

Landlord: /s/ SAM H. HAWKINS             ACCEPTED AND AGREED TO:
          ----------------------         FINOVA CAPITAL CORPORATION
   Plaza Del Oro Business Center
                                         By:    /s/ LINDA A. MOSCHITTO
By:                                             --------------------------------
    -----------------------------        Name:  Linda A. Moschitto
Name:     SAM H. HAWKINS                        --------------------------------
      ---------------------------        Title: Director-Contract Administration
Title: Owner                                    --------------------------------
      ---------------------------        Date:  October 15, 1999
Date:  08/26/99                                 --------------------------------
      ---------------------------

<PAGE>   13

                               LANDLORD'S WAIVER

This Landlord's waiver is made by the person identified below ("you" or
"Landlord") for FINOVA Capital Corporation ("we","us" or "FINOVA").

You are the owner of real property located at 8014 El Rio, Houston, Texas 77054.
You have entered into a lease for all or part of this property (the "Premises")
with Introgen Therapeutics, Inc. (the "Tenant").

We will be leasing to Tenant personal property, which may be machinery,
equipment, furniture, or fixtures. This personal property may be leased now or
in the future. We may be filing Uniform Commercial Code financing statements to
protect our interest in this personal property, as well as in any proceeds from
the property. This personal property and its proceeds are referred to as the
"Equipment." The Equipment will be located at the Premises.

We would not lease the Equipment to Tenant without this Landlord's Waiver. You
are benefiting from our leasing the Equipment to Tenant because the Equipment
will be used in Tenant's business. Revenues from Tenant's business can be used
by Tenant to pay you rent for the Premises. You intend to be legally bound by
this Landlord's Waiver.

1. WAIVER.

You acknowledge that you do not own the Equipment. You have no right or interest
in the Equipment. You waive any right under law to any lien on the Equipment.
You waive any right you may have under law or under your lease with Tenant to
levy on the Equipment or distrain the Equipment. You waive any right to make any
claim with respect to the Equipment.

2. PERSONAL PROPERTY.

The Equipment will remain personal property, even if it is attached to your real
estate.

3. REMOVAL OR SALE BY FINOVA

We may remove the Equipment from the Premises. You will not prevent or hinder us
from doing this. We will have no liability to you for this except for the cost
to repair damage actually caused by us to the Premises by removal. If you have
not re-let the Premises to somebody other than Tenant, we may sell the
Equipment from the Premises without having to pay rent.

4. SUCCESSORS AND ASSIGNS.

This Landlord's Waiver is binding upon and benefits your successors and assigns
(including any of your heirs or personal representatives) and our successors and
assigns.

LANDLORD:  TMX REALTY                    ACCEPTED AND AGREED TO:
          ----------------------         FINOVA CAPITAL CORPORATION

                                         By:    /s/ LINDA A. MOSCHITTO
By:  /s/ DAVID ENLOE                            --------------------------------
    -----------------------------        Name:  Linda A. Moschitto
Name:  David Enloe                              --------------------------------
      ---------------------------        Title: Director-Contract Administration
Title: President                                --------------------------------
      ---------------------------        Date:  October 15, 1999
Date:  08/27/99                                 --------------------------------
      ---------------------------

<PAGE>   14
                            SECRETARY'S CERTIFICATE

     I am the properly elected Secretary of Introgen Therapeutics, Inc., which
is a Delaware corporation (the "Corporation"). I certify to FINOVA CAPITAL
CORPORATION that:

          1. A true and correct copy of the Certificate of Incorporation of the
Corporation, as amended, is attached as Exhibit A to this certificate. The
amended Certificate of Incorporation attached hereto is still in effect as
written.

          2. A true and correct copy of the By-laws of the Corporation is
attached as Exhibit B to this Certificate. The By-laws have not been amended,
modified or supplemented. These are still in effect as written.

          3. The following officers of the Corporation have been properly
elected. They are still officers. Their true signatures appear below.

<TABLE>
<CAPTION>
          OFFICE                   NAME                      SIGNATURE
          ------                   ----                      ---------
<S>                           <C>                     <C>
President                     David G. Nance
                                                      --------------------------
Vice President and Chief
  Financial Officer           James W. Albrecht, Jr.  /s/ JAMES W. ALBRECHT, JR.
                                                      --------------------------

Secretary                     Rodney Varner           /s/ RODNEY VARNER
                                                      --------------------------
</TABLE>

          4. The Corporation is qualified to do business everywhere this is
required. It is in good standing in each of these jurisdictions.

          5. Resolutions properly adopted by the Board of Directors of the
Corporation appear below. These resolutions have not been revoked, amended,
modified or supplemented. They are still in effect as written.

          "WHEREAS, the Board of Directors of the Corporation believes that it
          is in the best interests of the Corporation to enter into a Master
          Lease Agreement with FINOVA Capital Corporation ("FINOVA");

          NOW, THEREFORE, be it:

          RESOLVED, that the Corporation is authorized to lease Equipment from
          FINOVA, pursuant to the terms of a Master Lease Agreement and all of
          its Exhibits, a copy of which has been delivered to each of the
          directors (the "Lease") to be signed and delivered by the Corporation,
          and be it further
<PAGE>   15
          RESOLVED, that the form of the Lease and all of its Exhibits are
          approved; and be it further

          RESOLVED, that the President or the Vice President and Chief Financial
          Officer of the Corporation, acting alone or together with a Secretary
          or any Assistant Secretary of the Corporation, are authorized and
          directed to sign and deliver and perform the Lease in the name and on
          behalf of the Corporation. Either of these officers are also
          authorized to sign and deliver the Exhibits and all other documents
          required by FINOVA. Either of these officer's are also authorized to
          make any changes or add additional terms as may appear in the final
          Lease and Exhibits signed by either of these officers; and be it
          further

          RESOLVED, that each said officer of the Corporation is authorized and
          directed to sign and deliver all other documents and to take all
          further lawful actions to implement the previous resolutions".

                                           /s/ RODNEY VARNER
                                           ---------------------------
                                                             Secretary

                                           Name:      RODNEY VARNER
                                                ----------------------
                                           Date: 8/20/99
                                                ----------------------

                                       2
<PAGE>   16
                                                                         [STAMP]

                                   EXHIBIT A

                     RESTATED CERTIFICATE OF INCORPORATION
                         OF INTROGEN THERAPEUTICS, INC.

     Introgen Therapeutics, Inc., a corporation organized and existing under
the laws of the State of Delaware, hereby certifies as follows:

     A. The name of the corporation is Introgen Therapeutics, Inc. The original
Certificate of Incorporation of the corporation was filed with the Delaware
Secretary of State on June 17, 1993, under the name of Intron Therapeutics,
Inc.

     B. Pursuant to Sections 242 and 245 of the Delaware General Corporation
Law, this Restated Certificate of Incorporation restates and integrates and
further amends the provisions of the Certificate of Incorporation of this
corporation.

     C. The text of the Certificate of Incorporation, as amended, is hereby
amended and restated in its entirety to read as follows.

     ONE. The name of this corporation is Introgen Therapeutics, Inc.

     TWO. The address of the corporation's registered office in the State of
Delaware is Corporation Trust Center, 1209 Orange Street, in the City of
Wilmington, County of New Castle. The name of its registered agent at such
office is The Corporation Trust Company.

     THREE. The purpose of the corporation is to engage in any lawful act or
activity for which corporations may be organized under the General Corporation
Law of Delaware.

     FOUR. This corporation is authorized to issue two classes of stock to be
designated Common Stock and Preferred Stock. The total number of shares of
Common Stock $0.001 par value, which this corporation has authority to issue is
20,000,000. The total number of shares of Preferred Stock, $0.001 par value,
which this corporation has authority to issue is 6,308,523. 3,011,423 shares of
Preferred Stock are designated Series A Preferred Stock ("Series A Preferred"),
2,114,100 shares of Preferred Stock are designated Series B Preferred Stock
("Series B Preferred") and 1,183,000 shares of Preferred Stock are designated
Series C Preferred Stock ("Series C Preferred").

<PAGE>   17

         The relative powers, preferences, special rights, qualifications,
limitations and restrictions granted to or imposed on the respective classes of
the shares of capital stock or the holders thereof are as follows:

         1. Dividends. The holders of the Series A Preferred, the Series B
Preferred and Series C Preferred shall be entitled, when and if declared by the
Board of Directors of the corporation, to dividends out of the corporation's
assets legally available therefor  at the rate of $0.10, $0.575 and $.865 per
share per annum, respectively. Such dividends on the Series A Preferred shall be
paid in preference and prior to any payment of any dividend on the Series B
Preferred, Series C Preferred and Common Stock. Such dividends on the Series B
Preferred shall be paid in preference and prior to any payment of any dividend
on the Series C Preferred and Common Stock. Such dividends on the Series C
Preferred shall be paid in preference and prior to any payment of any dividend
on the Common Stock. Thereafter, the holders of Common Stock shall be entitled,
when and if declared by the Board of Directors, to dividends out of the
corporation's assets legally available therefor. The right to such dividends on
shares of the Common Stock or Preferred Stock shall not be cumulative, and no
right shall accrue to holders of Common Stock or Preferred Stock by reason of
the fact that dividends on said shares are not declared in any prior period.

         2. Liquidation Preference. In the event of any liquidation, dissolution
or winding up of the corporation, either voluntarily or involuntarily,
distributions to the stockholders of the corporation shall be made in the
following manner:

                  (a) Series A Preference. The holders of the Series A Preferred
shall be entitled to receive, in preference and prior to any distribution of any
of the assets or surplus funds of the corporation to the holders of Series B
Preferred, Series C Preferred, and Common Stock, an amount equal to $1.00 per
share, plus a further amount equal to any dividends declared but unpaid on such
shares (the "Series A Preference"). If, upon such liquidation, dissolution or
winding up of the corporation, the assets of the corporation are insufficient to
provide for the cash payment of the full Series A Preference, such assets as are
available shall be distributed ratably among the holders of the Series A
Preferred in proportion to the full preferential amount each such holder is
otherwise entitled to receive.

                  (b) Series B Preference. After payment of the Series A
Preference, the holders of the Series B Preferred shall be entitled to receive,
in preference and prior to any distribution of any of the assets or surplus
funds of the corporation to the holders of Series C Preferred and Common Stock,
an amount equal to $5.75 per share, plus a further amount equal to any dividends
declared but unpaid on such shares (the "Series B Preference"). If, upon such
liquidation, dissolution or winding up of the corporation, the assets of the
corporation are insufficient to provide for the cash payment of the full Series
B Preference, such assets as are available shall be distributed ratably among
the holders of the Series B Preferred in proportion to the full preferential
amount each such holder is otherwise entitled to receive.

                  (c) Series C Preference. After payment of the Series A
Preference and the Series B Preference, the holders of the Series C Preferred
shall be entitled to receive, in preference and prior

                                      -2-
<PAGE>   18
to any distribution of any of the assets or surplus funds of the corporation to
the holders of Common Stock, an amount equal to $8.65 per share, plus a further
amount equal to any dividends declared but unpaid on such shares (the "Series C
Preference"). If, upon such liquidation, dissolution or winding up of the
corporation, the assets of the corporation are insufficient to provide for the
cash payment of the full Series C Preference, such assets as are available shall
be distributed ratably among the holders of the Series C Preferred in proportion
to the full preferential amount each such holder is otherwise entitled to
receive.

          (d)  After the payment of the setting apart of payment of the Series A
Preference, the Series B Preference and the Series C Preference, the holders of
Preferred Stock and Common Stock shall be entitled to receive all remaining
assets of this corporation pro rata based upon the number of shares of Common
Stock and Common Stock into which such shares of Preferred Stock could be
converted at the time of distribution.

          (e)  Consolidation or Merger. A merger, consolidation or sale of all
or substantially all of the assets of the corporation, or a series of related
transactions in which more than 50% of the voting power of the corporation is
disposed of, shall be deemed to be a liquidation, dissolution or winding up
within the meaning of this Section 2.

          (f)  Noncash Distributions. If any of the assets of the corporation
are to be distributed to the holders of Preferred Stock or Common Stock other
than in cash under this Section 2 (or for any purpose), then the Board of
Directors of the corporation shall promptly engage independent competent
appraisers to determine the value of the assets to be distributed. The
corporation shall, upon receipt of such appraiser's valuation, give prompt
written notice to each holder of shares of Preferred Stock or Common Stock of
the appraiser's valuation.

     3.   Voting Rights.

          (a)  Preferred Stock. Except as otherwise provided herein or required
by law, the holder of each share of Preferred Stock shall have voting rights and
powers equal to the voting rights and powers of the Common Stock. Each holder of
Preferred Stock shall be entitled to the number of votes equal to the number of
shares of Common Stock into which each share of Preferred Stock could be
converted pursuant to Section 4 hereof at the record date for the determination
of the stockholders entitled to vote on such matters or, if no such record date
is established, at the date such vote is taken. Fractional votes shall not,
however, be permitted and any fractional voting rights resulting from the above
formula shall be rounded to the nearest whole number (with one-half rounded
upward to one).

          (b)  Common Stock. Each holder of shares of Common Stock shall be
entitled to one vote for each share thereof held.

          (c)  Board of Directors. Notwithstanding the foregoing, (i) the
holders of the Series B Preferred Stock, voting as a separate class, shall be
entitled to elect one (1) director of the corporation; (ii) the holders of
Series A Preferred Stock, voting as a separate class, shall be entitled to

                                      -3-
<PAGE>   19
elect one (1) director of the corporation; and (iii) the holders of Common
Stock, voting as a separate class, shall be entitled to elect one (1) director
of the corporation. All remaining directors of the corporation will be elected
by the holders of Common Stock and Preferred Stock voting together.
Notwithstanding any Bylaw provision to the contrary, the stockholders entitled
to elect a particular director shall be entitled to remove such director or to
fill a vacancy in the seat formerly held by such director, all in accordance
with the applicable provisions of the General Corporation Law of Delaware.

                  (d)  Election by Ballot. The election of directors need not be
by written ballot unless the Bylaws of the corporation shall so provide.

         4. Conversion. The holders of Preferred Stock shall have conversion
rights as follows (the "Conversion Rights"):

                  (a)  Right to Convert. Each share of Preferred Stock shall be
convertible, at the option of the holder thereof, at any time after the date of
issuance of such share at the office of the corporation or any transfer agent
for such Preferred Stock. Each share of Preferred Stock shall be convertible
into the number of shares of Common Stock which results from dividing the
"Conversion Price" per share in effect for such series of Preferred Stock at the
time of conversion into the "Conversion Value" per share of such series of
Preferred Stock. The number of shares of Common Stock into which each series of
Preferred Stock is convertible is hereinafter collectively referred to as the
"Conversion Rate" for such series. The Conversion Price per share of (i) Series
A Preferred shall be $1.00, (ii) Series B Preferred shall be $5.75 and (iii)
Series C Preferred shall be $8.65. The Conversion Value per share of (i) Series
A Preferred shall be $1.00, (ii) Series B Preferred shall be $5.75 and (iii)
Series C Preferred shall be $8.65. The Conversion Price of each series of
Preferred Stock shall be subject to adjustment as hereinafter provided.

                  (b) Automatic Conversion. Each share of Preferred Stock shall
automatically be converted into shares of Common Stock at the then effective
Conversion Rate immediately upon the closing of an underwritten public offering
pursuant to an effective registration statement under the Securities Act of
1933, as amended, the aggregate gross proceeds of which equal or exceed
$10,000,000 (before expenses including underwriter discounts and commissions).

                  (c) Mechanics of Conversion. Before any holder of Preferred
Stock shall be entitled to convert the same into shares of Common Stock, he
shall surrender the certificate or certificates therefor, duly endorsed, at the
office of the corporation or of any transfer agent for such Preferred Stock and
shall give written notice to the corporation at such office that he elects to
convert the same. The corporation shall, as soon as practicable thereafter,
issue and deliver at such office to such holder of Preferred Stock a certificate
or certificates for the number of shares of Common Stock to which he shall be
entitled as aforesaid. Such conversion shall be deemed to have been made
immediately prior to the close of business on the date of such surrender of the
shares of Preferred Stock to be converted, and the person or persons entitled to
receive the shares of Common Stock issuable upon such conversion shall be
treated for all purposes as the record holder or holders of such shares of
Common Stock on such date.

                                      -4-
<PAGE>   20
                  (d)  Fractional Shares. No fractional shares of Common Stock
shall be issued upon conversion of the Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the
corporation shall pay cash equal to such fraction multiplied by the applicable
Conversion Price.

                  (e) Adjustment of Conversion Price. The Conversion Price of
each series of Preferred Stock shall be subject to adjustment from time to time
as follows:

                           (i) If the number of shares of Common Stock
outstanding at any time after the date hereof is increased by a stock dividend
payable in shares of Common Stock or by a subdivision or split-up of shares of
Common Stock, then, on the date such payment is made or such change is
effective, the Conversion Price for the Preferred Stock shall be appropriately
decreased so that the number of shares of Common Stock issuable on conversion of
any shares of the Preferred Stock shall be increased in proportion to such
increase of outstanding shares.

                           (ii) If the number of shares of Common Stock
outstanding at any time after the date hereof is decreased by a combination of
the outstanding shares of Common Stock, then, on the effective date of such
combination, the Conversion Price for such series shall be appropriately
increased so that the number of shares of Common Stock issuable on conversion of
shares of the Preferred Stock shall be decreased in proportion to such decrease
in outstanding shares.

                           (iii) In case the corporation shall declare a cash
dividend upon its Common Stock payable otherwise than out of retained earnings
or shall distribute to holders of its Common Stock shares of its capital stock
(other than Common Stock), stock or other securities of other persons, evidences
of indebtedness issued by the corporation or other persons, assets (excluding
cash dividends) or options or rights (excluding options to purchase and rights
to subscribe for Common Stock or other securities of the corporation convertible
into or exchangeable for Common Stock), then, in each such case, immediately
following the record date fixed for the determination of the holders of Common
Stock entitled to receive such dividend or distribution, the Conversion Price
for the Preferred Stock in effect thereafter shall be determined by multiplying
the Conversion Price for the Preferred Stock in effect immediately prior to such
record date by a fraction of which the numerator shall be an amount equal to the
remainder of ( ) the Current Market Price, of one share of Common Stock less (y)
the amount of such dividend in respect of one share of Common Stock or the fair
market value (as determined by the Board of Directors, whose determination shall
be conclusive) of the stock, securities, evidences or indebtedness, assets,
options or rights so distributed in respect of one share of Common Stock, as the
case may be, and of which the denominator shall be the Current Market Price of
one share of Common Stock. Such adjustment shall be made on the date such
dividend or distribution is made, and shall become effective at the opening of
business on the business day next following the record date for the
determination of stockholders entitled to such dividend or distribution.

                           (iv) In case, at any time after the date hereof, of
any capital reorganization (other than a reorganization covered by Section 2(c)
above), or any reclassification of the stock of the corporation (other than a
change in par value or as a result of a stock dividend or subdivision, split-up

                                      -5-
<PAGE>   21

or combination of shares), the shares of Preferred Stock shall, after such
capital reorganization or reclassification, be convertible into the kind and
number of shares of stock or other securities or property of the corporation to
which such holder would have been entitled if immediately prior to such capital
reorganization or reclassification he had converted his shares of Preferred
Stock into Common Stock. The provisions of this Section 4(e)(iv) shall similarly
apply to successive reorganizations, reclassifications, consolidations, mergers,
sales or other dispositions.

                  (v) All calculations under this Section 4 shall be made to the
nearest cent or to the nearest one hundredth (1/100) of a share, as the case may
be.

                  (vi) For the purpose of any computation pursuant to this
Section 4(e), the "Current Market Price" at any date of one share of Common
Stock, shall be deemed to be the average of the highest reported bid and the
lowest reported offer prices on the preceding business day as furnished by the
National Quotation Bureau, Incorporated (or equivalent recognized source of
quotations); provided, however, that if the Common Stock is not traded in such
manner that the quotations referred to in this Section 4(e) are available for
the period required hereunder, Current Market Price shall be determined in good
faith by the Board of Directors of the corporation, but if challenged by the
holders of more than 50% of the outstanding Preferred Stock, then as determined
by an independent appraiser selected by the Board of Directors of the
corporation, the cost of such appraisal to be borne by the challenging parties.

         (f) Minimal Adjustments. No adjustment in a Conversion Price need be
made if such adjustment would result in a change in a Conversion Price of less
than $0.01. Any adjustment of less than $0.01 which is not made shall be carried
forward and shall be made at the time of and together with any subsequent
adjustment which, on a cumulative basis, amounts to an adjustment of $0.01 or
more in a Conversion Price.

         (g) No Impairment. The corporation will not, through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed
hereunder by the corporation, but will at all times in good faith assist in the
carrying out of all the provisions of this Section 4 and in the taking of all
such action as may be necessary or appropriate in order to protect the
Conversion Rights of the holders of Preferred Stock against impairment. This
provision shall not restrict the corporation from amending its Certificate of
Incorporation in accordance with the General Corporation Law of the State of
Delaware.

         (h) Certificate as to Adjustments. Upon the occurrence of each
adjustment or readjustment of the Conversion Rate pursuant to this Section 4,
the corporation at its expense shall promptly compute such adjustment or
readjustment in accordance with the terms hereof and prepare and furnish to each
holder of Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or
readjustment is based. The corporation shall, upon written request at any time
of any holder of Preferred Stock, furnish or cause to be furnished to such
holder a like certificate setting forth (i) such adjustments and readjustments,
(ii) the Conversion Rate at the time in effect, and (iii) the number of shares
of

                                      -6-
<PAGE>   22
Common Stock and the amount, if any, of other property which at the time would
be received upon the conversion of the Preferred Stock held by such holder.

                  (i) Notices of Record Date. In the event of any taking by the
corporation of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any
dividend (other than a cash dividend) or other distribution, the corporation
shall mail to each holder of Preferred Stock at least twenty (20) days prior to
the date specified therein, a notice specifying the date on which any such
record is to be taken for the purpose of such dividend or distribution.

                  (j) Reservation of Stock Issuable Upon Conversion. The
corporation shall at all times reserve and keep available out of its authorized
but unissued shares of Common Stock solely for the purpose of effecting the
conversion of the shares of Preferred Stock such number of its shares of Common
Stock as shall from time to time be sufficient to effect the conversion of all
outstanding shares of Preferred Stock; and if at any time the number of
authorized but unissued shares of Common Stock shall not be sufficient to effect
the conversion of all then outstanding shares of Preferred Stock, the
corporation will take such corporate action as may, in the opinion of its
counsel, be necessary to increase its authorized but unissued shares of Common
Stock to such number of shares as shall be sufficient for such purpose.

                  (k) Notices. Any notice required by the provisions of this
Section 4 to be given to the holder of shares of Preferred Stock shall be
deemed given if deposited in the United States mail, postage prepaid, and
addressed to each holder of record at his address appearing on the books of the
corporation.

         5. Protective Provisions. So long as any shares of Preferred Stock
shall be outstanding, the corporation shall not, without first obtaining the
approval (by vote or written consent, as provided by law) of the holders of
more than 50% of the outstanding shares of Preferred Stock:

                  (a) alter or change the powers, preferences or special rights
of the Preferred Stock materially and adversely; or

                  (b) create any new class or series of shares having any
powers, preferences, or special rights superior to or on a parity with the
Preferred Stock; or

                  (c) effect a merger, consolidation or sale of substantially
all assets where the stockholders of the corporation before the transaction
hold less than 50% of the voting power of the surviving entity after the
transaction.

         FIVE. The corporation is to have perpetual existence.

                                      -7-

<PAGE>   23
     SIX. In furtherance and not in limitation of the powers conferred by
statute, the Board of Directors is expressly authorized to make, alter, amend
or repeal the Bylaws of the corporation.

     SEVEN. The number of directors which constitute the whole Board of
Directors of the corporation shall be as specified in the Bylaws of the
corporation.

     EIGHT. Meetings of stockholders may be held within or without the State of
Delaware, as the Bylaws may provide. The books of the corporation may be kept
(subject to any provisions contained in the statutes) outside the State of
Delaware at such place or places as may be designated from time to time by the
Board of Directors or in the Bylaws of the corporation.

     NINE. To the fullest extent permitted by the Delaware General Corporation
Law, a director of the corporation shall not be personally liable to the
corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director. Neither any amendment nor repeal of this Article NINE, nor
the adoption of any provision of this Certificate of Incorporation inconsistent
with this Article NINE, shall eliminate or reduce the effect of this Article
NINE in respect of any matter occurring, or any cause of action, suit or claim
that, but for this Article NINE, would accrue or arise, prior to such
amendment, repeal or adoption of an inconsistent provision.

     TEN. Advance notice of new business and stockholder nominations for the
election of directors shall be given in the manner and to the extent provided
in the Bylaws of the corporation.

     ELEVEN. The corporation reserves the right to amend, alter, change or
repeal any provisions contained in this Certificate, in the manner now or
hereafter prescribed by statute, and all rights conferred upon stockholders
herein are granted subject to this reservation.

     IN WITNESS WHEREOF, the corporation has caused this Certificate to be
signed by James W. Albrecht, Jr., its Vice President, and attested by Rodney
Varner, its Secretary, this 31st day of December, 1995.

                                         INTROGEN THERAPEUTICS, INC.

                                         By:  /s/ JAMES W. ALBRECHT, JR.
                                                  ---------------------------
                                                  James W. Albrecht, Jr., CFO
                                                  and Vice President

ATTEST:

/s/ J. RODNEY VARNER
---------------------------
J. RODNEY VARNER, Secretary

                                      -8-

<PAGE>   24
                      [WILSON & VARNER, L.L.P. LETTERHEAD]

                                 August 4, 1999

FINOVA Capital Corporation
10 Waterside Drive
Farmington, Connecticut 06032-3065

Gentlemen:

     We are counsel for Introgen Therapeutics, Inc. ("Lessee") and have advised
it in connection with the authorization, execution and delivery of the Master
Equipment Lease Agreement No. S7430 dated August 4, 1999, (the "Lease") and
Master Lease Schedule No. 1 thereto between FINOVA Capital Corporation
("Lessor") and Lessee, pursuant to which Lessee is leasing certain personal
property (the "Equipment").

     In connection with this opinion, we have examined, or caused to be
examined, the Lease, Master Schedule No. 1 thereto, and the other instruments
and documents executed by Lessee in connection therewith (all hereinafter
sometimes referred to collectively as the "Transactional Documents"), and have
also examined or caused to be examined the Certificate of Incorporation, the
By-Laws, records of the corporate proceedings of Lessee and such other records
and documents, and have made such investigations of law, as we have deemed
necessary. We understand that the Equipment to be leased will be located at 2250
and 2252 Holcombe Boulevard, Houston, Texas 77030.

     Upon the basis of the foregoing, it is our opinion that:

     1. Lessee is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and is qualified and in good
standing to do business wherever necessary to carry on its present business and
operations, including the jurisdiction(s) where the Equipment is or will be
installed.

     2. Lessee has the corporate power to engage in the transactions
contemplated by the Transactional Documents.

     3. The Transactional Documents have been duly authorized, executed and
delivered by Lessee, and constitute the valid, legal and binding obligations of
Lessee enforceable in accordance with their terms.

<PAGE>   25
FINOVA
August 4, 1999
Page 2

     4. No vote or consent of, or notice to, the holders of any class of stock
of Lessee is required, or if required, such vote, consent or notice has been
obtained or given, to authorize the execution, delivery and performance of the
Transactional Documents by Lessee and the consummation by Lessee of the
transactions contemplated by the Transaction Documents.

     5. Neither the execution and delivery by Lessee of the Transactional
Documents, nor the consummation by Lessee of the transactions contemplated
thereby, nor compliance by Lessee with the provisions thereof, (a) violate any
of the provisions of the Certificate of Incorporation or the By-Laws of Lessee,
(b) result in the creation (other than in favor of Lessor) of any lien, charge,
security interest or other encumbrance upon any of the Equipment or conflict
with or result in a breach of any of the terms, conditions or provisions of, or
constitute a default under any indenture, mortgage, deed of trust, agreement,
judgment, order, writ, injunction, decree, award or other instrument of any
other nature of which I have knowledge (after reasonable investigation) to which
Lessee is a party or by which it or its property is bound or affected, (c)
adversely affect in any manner Lessor's right, title and interest in any of the
Equipment or (d) to my knowledge, violate any statute, rule or regulation
applicable to Lessee.

     6. No consent, approval, withholding of objection or other authorization
of or by any court, administrative agency, other governmental authority or any
other person is required, except such consents, approvals or other
authorizations which have been duly obtained and are in full force and effect,
in connection with the execution, delivery or performance by Lessee of, or the
consummation by Lessee of the transactions contemplated by, the Transactional
Documents.

     7. After reasonable investigation, we know of no actions, suits or
proceedings pending or threatened in any court or before any administrative
agency or other governmental authority against or affecting Lessee, which, if
adversely decided will or could, individually or in the aggregate, materially
and adversely affect the business, operations, property or financial condition
of Lessee, or the ability of Lessee to perform any of its obligations under the
Transactional Documents.

     8. After reasonable investigation, we know of no Event of Default under the
Lease or event or condition which upon the passage of time, the giving of
notice, or both; would constitute such Event of Default, that exists or is
continuing.

     9. The title of Lessor to the Equipment is free and clear of any security
interest, lien or encumbrance granted by Lessee to any third party or any lien
arising by law for unpaid taxes of Lessee, other than any such taxes collected
by Lessor from Lessee.

<PAGE>   26
FINOVA
August 4, 1999
Page 3

     This opinion assumes that the Lease will be governed by the contractual
and general statutory and common law of Texas, and the general corporation law
of Delaware.

     No opinion is given with respect to the laws of Arizona or any other
state. No opinion is given as to the enforceability of the choice of law
provisions of the Lease, or whether or not the Lease is usurious or will be
usurious as administered.

     Lessor's rights may be modified or impacted by the generally applicable
rules of equity and/or the laws of bankruptcy, insolvency, and receivership.

     This opinion may be relied upon only by Lessor and its lenders and assigns.

                                                     Yours very truly,

                                                     WILSON & VARNER, L.L.P.

                                                     By: /s/ RODNEY VARNER
                                                        ------------------
                                                        Rodney Varner

<PAGE>   27
               ENVIRONMENTAL CERTIFICATE AND INDEMNITY AGREEMENT

                  THIS ENVIRONMENTAL CERTIFICATE AND INDEMNITY AGREEMENT (this
"AGREEMENT") is made as of August 20, 1999, by the undersigned, Introgen
Therapeutics, Inc., a Delaware corporation ("CUSTOMER"), in favor of FINOVA
CAPITAL CORPORATION, a Delaware corporation ("INDEMNITEE") and other Indemnified
Parties (defined below).

                                   RECITALS:

                  A. Indemnitee is entering into a lease transaction (the
"TRANSACTION") with Customer. The documents covering, evidencing, governing or
securing the Transaction are sometimes referred to herein collectively as the
"TRANSACTION DOCUMENTS". Pursuant to the Transaction and the Transaction
Documents executed in connection therewith, Indemnitee will lease to Customer
certain research and development, laboratory, manufacturing and computer
equipment and other personal property described in the Transaction Documents
(the "EQUIPMENT").

                  B. Indemnitee is unwilling to close the Transaction unless
Customer agrees to provide the indemnifications, certifications,
representations, warranties, and covenants and other matters described in this
Agreement for the benefit of Indemnified Parties.

                                   AGREEMENT

                  NOW THEREFORE, in order to induce the Indemnitee to close the
Transaction, and in consideration of the substantial benefit Customer will
derive from the Transaction, Customer agrees as follows:

                            ARTICLE 1 - DEFINITIONS

                  Capitalized terms used herein and not specifically defined
herein shall have the respective meanings ascribed to such terms in the
Transaction Documents. As used in this Agreement, the following terms shall have
the following meanings:

                  The term "Disclosure Statement" means that certain
Environmental Disclosure Statement attached hereto.

                  The term "EHS Permits" means all environmental, health and
safety permits, licenses, consents and authorizations required under any
Environmental Law.

                  The term "Environmental Conditions" means the presence or
release of any Hazardous Material on, in, about, under or from the Equipment, as
applicable.

                  The term "Environmental Law" means any present or future
federal, state or local laws, statutes, codes, ordinances, rules, regulations,
standards, policies, court orders, decrees, administrative orders, guidelines or
other governmental directives, as well as common law, relating to protection of
human health or the environment, relating to Hazardous Materials that apply to
Customer or the Equipment and relate to Hazardous Materials.

                  The term "Environmental Lien" means a lien in favor of any
Governmental Authority for any: (a) liability under any Environmental
Requirement; or (b) damages arising from, or costs incurred by such Governmental
Authority in response to a Release.

                  The term "Environmental Report" means the environmental site
assessment reports for the Equipment obtained by Indemnitee from its
environmental consultant or an environmental consultant approved by Indemnitee,
in connection with the Transaction.
<PAGE>   28

         The term "Environmental Requirement" means all Environmental Laws or
EHS Permits.

         The term "Governmental Authority" means any federal, state or local
agency, department, court or other administrative, legislative or regulatory
federal, state or local governmental body, or any private individual or entity
in place of such entities.

         The term "Hazardous Materials" shall mean (a) petroleum and petroleum
derived substances, products, compounds and wastes, including gasoline, diesel
fuel and oil; (b) explosive or flammable materials; (c) radioactive materials;
(d) polychlorinated biphenyls ("PCBs") and compounds containing them; (e) lead
and lead-based paint; (f) asbestos or asbestos-containing materials; (g) medical
wastes; (h) any substance the presence of which is prohibited by any
Environmental Requirement; (i) any substance that, pursuant to any Environmental
Requirement, requires special handling; (j) any other material or substance now
or in the future defined as or regulated under any Environmental Requirement as
a "hazardous substance," "hazardous material," "hazardous waste", "toxic
substance", "toxic pollutant", "contaminant", or "pollutant".

         The term "Indemnified Parties" means indemnitee, any person or entity
who is or will have been involved in the origination of the Transaction, any
person or entity who is or will have been involved in the servicing of the
Transaction, any person or entity in whose name any obligation or any
encumbrance created by the other Transaction Documents is or will have been
recorded, persons and entities who may hold or acquire or will have held a full
or partial interest in the Transaction (including, but not limited to, investors
in securities backed by the Transaction, as well as custodians, trustees and
other fiduciaries who hold or have held a full or partial interest in the
Transaction for the benefit of third parties) as well as the respective
directors, officers, shareholders, employees, agents, representatives,
contractors, subcontractors, affiliates, subsidiaries, participants, successors
and assigns of any and all of the foregoing (including but not limited to any
other person or entity who holds or acquires or will have held a participation
or other full or partial interest in the Transaction or the Equipment, whether
during the term of the Transaction or as a part of or following a foreclosure of
the Transaction or exercise of any remedies under the other Transaction
Documents, and including, but not limited to, any successors by merger,
consolidation or acquisition of all or a substantial portion of Indemnitee's
assets and business).

         The term "Legal Action" means any claim, suit or proceeding, whether
administrative or judicial in nature.

         The term "Losses" shall mean any and all claims, demands, suits,
liabilities (including, without limitation, strict liabilities), actions,
proceedings, obligations, debts, damages, losses, costs, expenses, fines,
penalties, charges, fees, expenses, judgments, awards, amounts paid in
settlement of whatever kind or nature (including but not limited to attorneys',
accountants', engineers' and contractors' fees and other costs) arising out of
any Environmental Condition. "Losses" shall include, without limitation, all
past, current and future expenses, arising out of: (i) any pending, threatened
or completed action by a Governmental Authority or any person or entity for
Equipment damage, bodily injury or personal injury (including any appeals
whether instituted by Customer, any Governmental Authority or any other person
or entity); (ii) any injury, investigation, audit, study, assessment, notice of
violation, administrative complaint, summons, citation, directive or judicial
complaint; (iii) any development of remedial or response plans; and (iv) any
conduct or activity in any way associated therewith.

         The term "Release" with respect to any Hazardous Material means actual
or threatened release, deposit, discharge, emission, leaking, leaching,
spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping,
dumping, disposing or other movement of Hazardous Materials in, under, on, above
or from the Equipment, as applicable.

                                      -2-
<PAGE>   29
         The term "Remedial Action" means actions required to: (a) clean up,
remove, treat or otherwise address any Release of Hazardous Materials; (b)
prevent or minimize the Release of Hazardous Materials; or (c) determine if a
remedial response or corrective action is needed, design an appropriate
response, compile necessary data and reports, conduct pre- and post-remedial
investigation, monitoring, operation, maintenance and care.

                          ARTICLE 2 - INDEMNIFICATION

         2.1 INDEMNIFICATION. Customer covenants and agrees at its sole cost and
expense, to protect, defend, indemnify, release and hold Indemnified Parties
harmless from and against any and all Losses imposed upon or incurred by or
asserted against any Indemnified Parties and directly or indirectly arising out
of or in any way relating to any one or more of the following: (a) any presence
of any Hazardous Materials in, on, above, under or from the Equipment, as
applicable; (b) any past, present or threatened Release of Hazardous Materials
in, on, above, under or from the Equipment, as applicable; (c) any activity by
Customer, any person or entity affiliated with Customer or other user of the
Equipment in connection with any actual, proposed or threatened use, treatment,
storage, holding, existence, disposition or other Release, generation,
production, manufacturing, processing, refining, control, management, abatement,
removal, handling, transfer or transportation to or from the Equipment of any
Hazardous Materials at any time located in, under, on or above the Equipment or
any actual or proposed remediation of any Hazardous Materials at any time
located in, under, on or above the Equipment, whether or not such remediation is
voluntary or pursuant to court or administrative order, including but not
limited to any removal, remedial or corrective action; (d) any past, present or
threatened non-compliance or violations of any Environmental Requirements in
connection with the Equipment, including but not limited to any failure by
Customer, any person or entity affiliated with Customer, and any tenant or other
user of the Equipment to comply with any order of any Governmental Authority in
connection with any Environmental Requirements; (e) the imposition, recording or
filing or the threatened imposition, recording or filing of any Environmental
Lien encumbering the Equipment; (f) any acts of Customer, any person or entity
affiliated with Customer, and any tenant or other user of the Equipment relating
to environmental matters in (i) arranging for disposal or treatment, or
arranging with a transporter for transport for disposal or treatment, of
Hazardous Materials at any facility or incineration vessel containing such or
similar Hazardous Materials or (ii) accepting any Hazardous Materials for
transport to disposal or treatment facilities, incineration vessels or sites
from which there is a Release, or a threatened Release of any Hazardous
Materials which causes the incurrence of costs for remediation; and (g) any
misrepresentation or inaccuracy in any representation or warranty or material
breach or failure to perform any covenants or other obligations pursuant to this
Agreement or the other Transaction Documents relating to environmental matters;
provided, however, that Customer shall have no obligation to Indemnitee or any
other Indemnified Party under this Section 2.1 which results from the gross
negligence or willful misconduct of Indemnitee or such other Indemnified Party.

         2.2 DUTY TO DEFEND AND ATTORNEYS AND OTHER FEES AND EXPENSES. Upon
written request by any Indemnified Party, Customer shall defend the indemnified
claims (if requested by any Indemnified Party, in the name of the Indemnified
Party) by attorneys and other professionals reasonably approved by the
Indemnified Parties and Customer shall bear the cost thereof.

         2.3 NOTICE OF LEGAL ACTIONS. Customer shall, within five (5) business
days of receipt thereof, give written notice to Indemnitee of (i) any notice,
advice or other communication from any Governmental Authority with respect to
Hazardous Materials on, from or affecting the Equipment, (ii) any matter which
would constitute a breach of or deviation from any representation, warranty,
covenant or agreement contained herein; and (iii) any Legal Action brought
against such party or related to the Equipment, with respect to which Customer
may have liability under this Agreement. Upon request, Customer shall provide to
Indemnitee copies of any documents pertaining to any of the above-described
matters in this Section.

                                      -3-
<PAGE>   30
            ARTICLE 3 - REPRESENTATIONS AND WARRANTIES AND COVENANTS

                  3.1 REPRESENTATIONS, WARRANTIES AND COVENANTS. Except as
described in the Disclosure Statement, Customer, to the best of its knowledge,
hereby represents, covenants and warrants to Indemnitee as follows:

                           (a) The Equipment is not listed on any federal,
state, or local list identifying properties with a known or suspected Release.
Customer is unaware of any condition that, if known to a Governmental Authority,
would require (1) the Equipment be listed or (2) Remedial Action.

                           (b) The operation of or on the Equipment has never
been, and is not anticipated to be, for the purpose of the manufacture,
generation, Release, or refining of any Hazardous Material, except in compliance
with all applicable Environmental Laws.

                           (c) Customer obtained, and is and will continue to be
in material compliance with, all EHS Permits necessary for the ownership, use
and operation of the Equipment.

                           (d) No Environmental Lien has, is, or is anticipated
to be attached to the Equipment or any portion thereof.

                           (e) Customer is not, has not, and does not anticipate
being, subject to any action by a Governmental Authority regarding: (i) the
violation of any Environmental Requirement; (ii) any Remedial Action; (iii) any
liability arising out of or related to the presence or Release of any Hazardous
Material resulting from or pertaining to the operation, use or ownership of the
Equipment.

                  3.2 CONFLICTS. In the case of any conflict between the
provisions of this Agreement and the provisions of any other Transaction
Documents pertaining to environmental matters, the provisions of this Agreement
shall control.

                  3.3 REMEDIAL ACTION. Customer, at its own cost, shall perform
all Remedial Action to result in the preservation of the current economic use of
the Equipment, and shall be conducted: (a) in accordance with all Environmental
Requirements; and (b) in accordance with any Governmental Authority orders,
directives, and/or terms, whether negotiated or imposed.

                  3.4 SITE ASSESSMENTS. At any time during the continuance of a
default (a "Default") described in the Transaction Documents, if Indemnitee
reasonably believes that Hazardous Materials (other than those described in the
Disclosure Statement) affect the Equipment, Indemnitee may contract for the
services of any environmental engineering company ("Environmental Consultant")
to perform an environmental site assessment ("Site Assessment") to determine
whether any Environmental Condition exists that could result in the diminution
of the value of the Equipment, and/or any liability, cost, or expense to the
owner, occupier, or operator of the Equipment. Site Assessments may be performed
at any time during the continuance of a Default, upon reasonable notice and with
minimal interference with Customer's affairs to the extent practicable, as
reasonably determined by Indemnitee. Once a Site Assessment is contracted for,
the Site Assessment may be performed notwithstanding that such a Default was
cured. Customer will not impede or interfere with any such Site Assessment, and
will cooperate fully with the Environmental Consultant including providing all
historical and operating information for the Equipment. The Environmental
Consultant, and its employees, agents, subcontractors, and assigns, are hereby
authorized to examine or enter upon the Equipment, as applicable, for such
purposes and are further authorized to perform tests on the Equipment necessary
to conduct the Site Assessment. On request, Indemnitee shall make the results
of such Site Assessments available to Customer. The cost of performing the Site
Assessments, including, without limitation, sampling and monitoring, the
preparation of any reports or studies, and the cost of laboratory analysis,
shall be paid by Customer upon demand.

                                      -4-
<PAGE>   31

                              ARTICLE 4 - GENERAL

               4.1 ENFORCEMENT. Indemnified Parties may enforce the obligations
of Customer under this Agreement without first resorting to or exhausting any
security or collateral or without first having recourse to the other Transaction
Documents or any of the Equipment, through foreclosure proceedings, exercise of
remedies under the other Transaction Documents or otherwise, provided, however,
that nothing herein shall inhibit or prevent Indemnitee from suing on the other
Transaction Documents or from foreclosing or exercising any other rights and
remedies under the other Transaction Documents.

               4.2 WAIVERS. COMPANY HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY LAW, THE RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM, WHETHER IN CONTRACT, TORT OR OTHERWISE, RELATING DIRECTLY OR
INDIRECTLY TO THE TRANSACTION, THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS
OR ANY ACTS OR OMISSIONS OF ANY INDEMNIFIED PARTIES IN CONNECTION THEREWITH.

               4.4 SURVIVAL. The indemnification obligations of Customer
contained in this Agreement shall survive payment and satisfaction in full of
all obligations of Customer to Indemnitee.

                           ARTICLE 5 - MISCELLANEOUS

               5.1 NOTICES. All notices or other written communications
hereunder shall be given in accordance with the requirements of the other
Transaction Documents.

               5.2 NO THIRD-PARTY BENEFICIARY. The terms of this Agreement are
for the sole and exclusive protection and use of Indemnified Parties. No party
shall be a third-party beneficiary hereunder, and no provision hereof shall
operate or inure to the use and benefit of any such third party. It is agreed
that those persons and entities included in the definition of Indemnified
Parties are not such excluded third party beneficiaries.

               5.3 DUPLICATE ORIGINALS; COUNTERPARTS. This Agreement may be
executed in any number of duplicate originals and each duplicate original shall
be deemed to be an original. This Agreement may be executed in several
counterparts, each of which counterparts shall be deemed an original instrument
and all of which together shall constitute a single Agreement. The failure of
any party hereto to execute this Agreement, or any counterpart hereof, shall not
relieve the other signatories from their obligations hereunder.

               5.4 NO ORAL CHANGE. This Agreement, and any provisions hereof,
may not be modified, amended, waived, extended, changed, discharged or
terminated orally or by any act or failure to act on the part of Customer or any
Indemnified Party, but only by an agreement in writing signed by the party
against whom enforcement of any modification, amendment, waiver, extension,
change, discharge or termination is sought.

               5.5 HEADINGS, ETC. The headings and captions of various
paragraphs of this Agreement are for convenience of reference only and are not
to be construed as defining or limiting, in any way, the scope or intent of the
provisions hereof.

               5.6 RIGHTS CUMULATIVE. The rights and remedies herein provided
are cumulative and not exclusive of any rights or remedies which Indemnitee has
under the other Transaction Documents or would otherwise have at law or in
equity.

               5.7 GOVERNING LAW. This Agreement shall be governed, construed,
applied and enforced in accordance with the laws of the state in which the
Equipment is located.

                                      -5-
<PAGE>   32

               IN WITNESS WHEREOF, this Agreement has been executed by Customer
and is effective as of the day and year first above written.

                                             CUSTOMER:

                                             INTROGEN THERAPEUTICS, INC.
                                             a Delaware corporation

                                             By: /s/ JAMES W. ALBRECHT, JR.
                                                 --------------------------
                                             Name: JAMES W. ALBRECHT, JR.
                                                   ------------------------
                                             Title: Chief Financial Officer
                                                    -----------------------

                                      -6-
<PAGE>   33

                              DISCLOSURE SCHEDULE
                                       TO
               ENVIRONMENTAL CERTIFICATE AND INDEMNITY AGREEMENT

<PAGE>   34
                           PROGRESS PAYMENT AGREEMENT

         Agreement made this 30 day of September, 1999 between FINOVA Capital
Corporation ("we", "us" or "FINOVA") and Introgen Therapeutics, Inc. ("you" or
"Lessee")

                                   BACKGROUND

         1. You and we have entered into a certain Master Lease Schedule No. 01
to Equipment Lease No. S7430, dated August 4, 1999 (both, the "Lease").

         2. FINOVA has agreed, under certain circumstances, to purchase certain
equipment (the "Equipment") from certain suppliers (the "Suppliers") or
reimburse Lessee for deposits already paid to vendors designated by you having a
cost not to exceed $1,555,000 (the "Total Cost") and to lease the Equipment to
you under the terms and conditions of the Lease.

         3. The agreement between you and Suppliers with respect to the
Equipment (the "Agreement") provides for payment of the Total Cost to the
Suppliers prior to the date that all of the Equipment has been delivered,
installed and accepted in writing by You.

         4. You have requested that we advance a part of the Total Cost to the
Suppliers or reimburse Lessee for deposits already paid to vendors (each, an
"Advance") prior to the delivery and acceptance of the Equipment by you.

         5. Prior to any Advance, you will provide to us the name of the
Suppliers, a detailed description of the Equipment for which the Advance
relates, the amount of the Advance, and such other information requested by us.

         6. Subject to the term of this Agreement, we are will to make such
Advances.

            You and we agree as follows:

         1. The Equipment described in each request for Advance must be
acceptable to us, as determined solely by us.

         2. We shall, upon receipt of your written request, make Advances to
such Suppliers or we will reimburse you for deposits already paid to vendors,
provided the aggregate Advances for all of the Equipment is not more than the
Total Cost. Each written request from you shall be on the form attached as
Exhibit I. You will also provide us with a copy of the original invoice
indicating the work completed to date as well as the amount FINOVA is to issue
to Supplier or reimburse to you. As the earlier of (i) the date that we have
advanced the Total Cost or (ii) December 30, 1999 (the "Outside Date"), you
agree to execute a Delivery and Acceptance Receipt setting forth, in detail,
each item of Equipment. If on, the second business day preceding the Closing
Date for each Schedule, the highest yield for four year U.S. Treasury Notes
published in The Wall Street Journal on such date is greater or less than the
yield as published on May 28, 1999, the Monthly Rent Payments shall be increased
or decreased (point for point) to reflect such change in the yield. The yield as
of May 28, 1999 was 5.73%. As of the Closing Date, the Monthly Rent Payments
shall be fixed for the entire Term of such Schedule based on an interest rate
equal to the then current Index Rate plus 6.91%. We will have no obligation to
make any Advances (or any portion of an Advance) after the Outside Date.

         3. On and after the first Advance, you agree to pay us interest
computed at the rate of one (1%) percent per month on a daily basis on all
Advances from the date of each Advance until the date the first rent payment us
due under the Lease (the "Rent Commencement Date"). All accrued interest shall
be payable by you to us upon the Rent Commencement Date.
<PAGE>   35

         4. In the event that you fail to accept all of the Equipment and to
sign and deliver to us the Delivery and Acceptance Receipt on or before the
Outside Date, you must upon our demand (a) pay to us all Advances made by us for
the purchase of the Equipment, plus all accrued interest as set forth in
Paragraph 3 above and (b) pay to us a cancellation fee equal to 5% of the total
cost to purchase the Equipment. In the event you fail to pay such amounts when
due, interest shall accrue at a default rate of five (5%) percent in addition to
the accrued interest set forth in Paragraph 3 (but in no more than the maximum
rate permitted by law.)

         5. You shall sign UCC Financing Statements for the Equipment and
provide all appropriate titling requirements, as we deem necessary. You will
also obtain satisfactory evidence of insurance as required by the terms and
condition of the lease.

         6. You acknowledge that any Equipment delivered to you shall be owned
by us free and clear of all liens, claims and interests of any other party and
subject to all of the terms and conditions of the Lease, unless otherwise
specifically provided in this Agreement. Failure by you to pay any sums when
due under this Agreement shall be an Event of Default under the Lease.

FINOVA CAPITAL CORPORATION

By  /s/ LINDA A. MOSCHITTO
    ----------------------
    Linda A. Moschitto

Title  Director - Contract Administration
       ----------------------------------

INTROGEN THERAPEUTICS, INC.

By /s/ JAMES W. ALBRECHT, JR.
   --------------------------
       James W. Albrecht, Jr.

Title Chief Financial Officer
     ------------------------

<PAGE>   36

                              [FINOVA LETTERHEAD]

                                REVISED 4/25/00

April 25, 2000

Mr. Jim Albrecht
Introgen Therapeutics, Inc.
301 Congress Avenue Suite 1850
Austin, TX 78701

Dear Jim:

This letter serves as notification that the Acquisition Cost and Monthly Rent
Payments for Master Lease Schedule No. 1 to Master Lease Agreement No. S7430
dated August 4, 1999 ("Master Lease") has been set in accordance with Section
Five of the Master Lease Schedule:

o    Acquisition Cost set at $1,475,758.16; and

o    Monthly Rent Payments set at $39,339.88 for 48 consecutive
     months; and

o    $26.6574 as the Lease Rate Factor adjusted for an increase in the
     four-year U.S. Treasury Note Yield from the Index Rate of 5.73%
     for May 28, 1999 to 6.34% for April 25, 2000; and

o    The Lease Term commencement date is April 30, 2000.

Sincerely,

FINOVA CAPITAL CORPORATION

<PAGE>   37

                          MASTER LEASE SCHEDULE NO. 1
                   TO MASTER LEASE NO. S7430001 (THE "LEASE")

SUPPLIER: As described in Schedule A.

LOCATION OF EQUIPMENT: As described in Schedule A.

ACQUISITION COST OF THE EQUIPMENT: $1,475,758.16

TERM OF SCHEDULE
RENTAL PAYMENTS: (48) Forty-eight successive Monthly Rental Payments each in the
amount of $38,915.74 per month, subject to adjustment as stated in Section 5,
plus any applicable sales/use tax. Your first payment is due on April 30, 2000.

LEASE RATE FACTOR: The Lease Rate Factor is $26.37 per $1,000 of Acquisition
Cost, subject to adjustment as stated in Section 5.

ADVANCE RENTALS: $38,915.74 Payable at the time of signing of this Schedule. To
be applied to the first Monthly Rental Payment.

ADDITIONAL TERMS:

1.       LEASE OF EQUIPMENT. FINOVA Capital Corporation ("we" or "Lessor")
agrees to lease to the Lessee named below ("you" or "Lessee") the Equipment
listed on Schedule "A" attached to this Master Lease Schedule (the "Equipment").
You agree to lease the Equipment from us. The lease of the Equipment is under
the terms of the Master Lease Agreement (the "Lease") named above.

2.       EQUIPMENT ACCEPTANCE DATE. The Equipment shall be delivered, installed
and accepted no later than June 30, 2000.

3.       OPTION TO PURCHASE. At the end of the Term of this Schedule, you have
an option to purchase all of the Equipment. However, you may not exercise this
option if you are in default under this Schedule or under any other lease or
agreement that you have with us. you will give us no less than 120 days written
notice if you exercise this option. You may not purchase less than all of the
Equipment. If you purchase the Equipment, you will purchase it "AS IS" and
"WHERE IS." The purchase price will be $1.00, plus any applicable sales or
other taxes.

4.       RESALE. If you do not purchase the Equipment, you give us your
permission to try to resell the Equipment from your Location. We may start doing
this 120 days before the end of the Term of this Schedule. You must keep the
Equipment working while we try to sell it. You will also make sure we have all
electrical power, lighting, heat and water that we need to comfortably
demonstrate the Equipment to buyers. We also have your permission to auction the
Equipment at your Location.

5.       INDEX. Two business days prior to the beginning of the Term of this
Schedule, we will read The Wall Street Journal to determine the published
highest yield on four (4) year U.S. Treasury Notes. This yield is called the
"Index". If the Index is not published in The Wall Street Journal, we will
determine it from another reliable source. If the Index is higher or lower than
5.73% as published on May 28, 1999, we will increase or decrease the rent
payments (point for point) under this Schedule to reflect this increase or
decrease. As of the Closing Date, the Monthly Rent Payments shall be fixed for
the entire term of the Schedule based on an interest rate equal to the then
current Index Rate plus 6.91%. We will give you notice of any increase or
decrease as soon as we can. You will pay the increased or decreased rent
payments unless we have made an obvious mistake in our calculations.

                                        1
<PAGE>   38

LESSOR:                                    LESSEE:
FINOVA CAPITAL CORPORATION                 INTROGEN THERAPEUTICS, INC.
10 WATERSIDE DRIVE                         301 CONGRESS AVENUE
FARMINGTON, CONNECTICUT 06032              AUSTIN, TX 78701

BY: /s/ LINDA A. MOSCHITTO                 BY: /s/ JAMES W. ALBRECHT, JR.
   --------------------------------------     ---------------------------------

PRINTED NAME:  Linda A. Moschitto          PRINTED NAME: James W. Albrecht, Jr.
             ----------------------------               -----------------------

TITLE: Director - Contract Administration  TITLE: CFO
      -----------------------------------        ------------------------------

DATE ACCEPTED: April 11, 2000              DATE ACCEPTED: April 4, 2000
              ---------------------------                ----------------------

                                       2
<PAGE>   39

                                   SCHEDULE A

                                       TO

                          MASTER LEASE SCHEDULE NO. 1

                      INTROGEN THERAPEUTICS, INC. (LESSEE)
                      FINOVA CAPITAL CORPORATION (LESSOR)

The equipment consists of the following:

<TABLE>
<CAPTION>
                                                                                 INVOICE                    EQUIPMENT
QUANTITY          DESCRIPTION                CHECK NO.                           NUMBER                     COST
--------          -----------                ---------                           ------                     ----
<S>               <C>                        <C>                                 <C>                        <C>
1                 Modular Clean Room         19122, 15017, 17780, 17781          Project # 5891-TX          $1,475,758.16
                                             17782, 17783, 18127, 18592
                                             18593, 20606
</TABLE>

Subcontractor -- MSS Clean Technology, Inc.

LOCATION OF EQUIPMENT:
----------------------
2250 and 2252 Holcombe Boulevard Houston, Texas 77030

<PAGE>   40
                      DELIVERY AND ACCEPTANCE CERTIFICATE
                                       TO
                          MASTER LEASE SCHEDULE NO. 1

Introgen Therapeutics, Inc. ("you" or "Lessee") certifies that:

o  You have received the Equipment described on Schedule "A" to the Master Lease
   Schedule.

o  This is the Equipment that you selected and that you wanted.

o  Unless we agreed otherwise, you did not receive any of the Equipment before
   you and we each signed the Lease.

o  The Equipment has been installed.

o  You have inspected the Equipment.

o  The Equipment works to your complete satisfaction.

o  You accept the Equipment.

You understand that FINOVA Capital Corporation ("we" or "Lessor") are relying
on this Certificate, since we will not pay for the Equipment unless you sign
this Certificate and give it to us.

You also certify that:

WE DID NOT MANUFACTURE OR SUPPLY THE EQUIPMENT. WE ARE NOT A DEALER IN THE
EQUIPMENT. INSTEAD, YOU CHOSE THE EQUIPMENT. WE DO NOT MAKE ANY WARRANTY AS TO
THE EQUIPMENT. WE DO NOT MAKE ANY WARRANTY AS TO "MERCHANTABILITY" OR
"SUITABILITY" OR "FITNESS FOR A PARTICULAR PURPOSE" OR "NONINFRINGEMENT" OF ANY
PATENT, COPYRIGHT OR OTHER INTELLECTUAL PROPERTY RIGHT. WE WILL NOT BE
RESPONSIBLE FOR ANY LOSS, DAMAGE OR INJURY TO YOU OR ANYBODY ELSE AS A RESULT OF
ANY DEFECTS, HIDDEN OR OTHERWISE, IN THE EQUIPMENT UNDER "STRICT LIABILITY" LAWS
OR ANY OTHER LAWS. WE WILL NOT BE RESPONSIBLE FOR ANY INDIRECT, SPECIAL OR
CONSEQUENTIAL DAMAGES, LOSS OF PROFITS OR GOODWILL. WE MAY ASSIGN THIS LEASE.
YOU MAY NOT RAISE ANY DEFENSE, COUNTERCLAIM OR OFFSET AGAINST THE ASSIGNEE.

Introgen Therapeutics, Inc.
(Lessee)

By /s/ JAMES W. ALBRECHT, JR.
   --------------------------
Title  CFO
     ------------------------

Date Equipment Accepted:  4/6/00
                        ---------------------------------
Date Equipment Delivered, if different
                                      -------------------

<PAGE>   41

                          INTROGEN THERAPEUTICS, INC.

                            CONTACT INFORMATION FORM

         Please provide us with the names and telephone numbers of the
         individuals that we should contact when inquiring about the following:

                  1. DOCUMENTATION QUESTIONS

                  2. ACCOUNTS PAYABLE

                  3. EQUIPMENT QUESTIONS

                  4. INSURANCE QUESTIONS

1. NAME: JANIE W. PEPPARD                    PHONE: 512-708-9310 ext. 324
        -----------------------------              --------------------------
2. NAME: JANIE W. PEPPARD                    PHONE: 512-708-9310 ext. 324
        -----------------------------              --------------------------
                                             FAX:   512-708-9311
                                                   --------------------------
3. NAME: SONYA DON                           PHONE: 713-610-4011
        -----------------------------              --------------------------
4. NAME: JANIE W. PEPPARD                    PHONE:  512-708-9310 ext. 324
        -----------------------------              --------------------------

<PAGE>   42
                           INVOICING INFORMATION FORM

BILLING ADDRESS: INTROGEN THERAPEUTICS, INC.
                 ---------------------------
                 301 CONGRESS AVENUE
                 ---------------------------
                 SUITE 1850
                 ---------------------------
                 AUSTIN, TX 78701
                 ---------------------------

CONTACT NAME:    JANIE W. PEPPARD
                 ---------------------------
CONTACT PHONE:   512.708.9310 ext 324
                 ---------------------------
CONTACT FAX:     512.708.9311
                 ---------------------------

<PAGE>   43
                             YEAR 2000 QUESTIONNAIRE

The issue of chip-driven equipment shutting down or mis-identifying information
is a critical one facing many of us as the year 2000 approaches. As a source of
capital for you business, we need to be aware of how you expect this issue to
impact your operations. Please have this questionnaire completed by an
appropriate officer of your company - whoever is in the best position to be
aware of the technical condition of your electronic equipment. While these are
yes-no questions, we encourage you to include comments you believe would help us
to understand any issues you may have.

Company Name:      INTROGEN THERAPEUTICS, INC.
                   ----------------------------------
Respondent's Name: JAMES W. ALBRECHT, JR.
                   ----------------------------------
Phone Number:      (512) 708-9310 X 323
                   ----------------------------------
Date Completed:    9-4-99
                   ----------------------------------

<TABLE>
<CAPTION>
                                                                      Yes       No        N/A
                                                                      ---       --        ---
<S>                                                                   <C>       <C>       <C>
1. Has the company completely inventoried its software, hardware,
   and telecommunications?                                             X

2. Has the company identified all equipment with date-sensitive
   operating controls such as phones, elevators, HVAC, security
   systems, manufacturing equipment, etc.?                             X

3. Do you know what is not Year 2000 compliant?                        X

4. Has the company verified that vendor-supplied systems will be
   Year 2000 compliant?                                                X

5. Has the company verified Year 2000 compliance of outside data-
   processing companies and established a testing time frame?          X

6. Does the company have any ongoing or long-term contracts that
   could subject it to liability if it failed to perform as a
   result of Year 2000 compliance failure?                                      X

7. Does the company already have in place contingency plans for
   mission critical systems?                                           X

8. Has your company developed a comprehensive plan for making it
   protected from Year 2000 compliance problems?                       X
</TABLE>

What would be the major impact on your business if your non-compliant situations
weren't fixed?

 LIMITED IMPACT
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Other Comments:

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
[SIGN HERE]

The above information is true and correct:

By  /s/ JAMES W. ALBRECHT, JR.
   ---------------------------
    CHIEF FINANCIAL OFFICER
<PAGE>   44

                              [FINOVA LETTERHEAD]

August 4, 1999

Mr. James Albrecht Jr.
Introgen Therapeutics, Inc.
301 Congress Avenue
Austin, TX  78701

RE: Insurance Requirements

Dear Mr. Albrecht:

The Lease Documents of FINOVA Capital Corporation ("Lessor") require Introgen
Therapeutics, Inc. ("Lessee") to obtain before funding and maintain throughout
the term of the Lease, insurance coverage insuring the Collateral as required
by, written by insurers, and in amounts and forms satisfactory to Lessor. Our
current requirements are outlined below. These requirements may be amended by
Lessor to reflect changes in the insurance industry or your business. You will
receive advance written notice of any amendments to the requirements.

(a) "ISO Special Causes of Loss Form", or equivalent thereof, property and/or
    builder's risk insurance, including, but not limited to, boiler and
    machinery, wind and hail, earthquake and flood insurance, insuring the
    Collateral and all replacements and additions thereto in an amount not less
    than the full insurable value on a replacement cost basis of the insured
    Collateral.

(b) Comprehensive third party bodily injury and property damage liability
    insurance on an occurrence basis, including coverage for
    "premises/operations", "products and completed operations", "professional",
    and "blanket contractual" liabilities.

(c) Business Interruption insurance in a limit sufficient to insure not less
    than a six month loss of income and/or Extra Expense Insurance.

(d) Such other insurance with respect to the Collateral as may be required by
    Lessor.

Insurance as outlined in (a) and (d) above shall (i) include a clause naming
Lessor as Mortgagee and/or Lessors Loss Payable, (ii) identify the Collateral
insured, (iii) state the applicable amount of insurance and (iv) provide the
Lessor may file proofs of loss and agree to the adjustment of any claims on
behalf of the Lessee should the Lessee fail to promptly do so. Insurance as
outlined in (b) and (c) above shall include clauses which (i) name Lessor as
an Additional Insured and (ii) provide that all insurance, except the limits
of liability, operate as if there were a separate policy covering each insured.

All insurance shall (i) be provided at Lessee's expense with insurers rated "A
VIII" by A.M. Best Company, Inc. (or the future equivalent thereof) or as
otherwise approved by Lessor, (ii) provide Lessor with thirty (30) days advance
written notice of cancellation and/or material change in coverage directly from
insurers, (iii) be primary and without the right of contribution from any other
insurance not specifically purchased by the Lessee to be excess of, or in
contribution with, the insurance required herein, (iv) include a waiver of any
subrogation rights Lessee's insurers may have against Lessor, (v) provide that
all insurance shall insure the interest of Lessor regardless of any breach or
violation by Lessee or any other party or entity of any warranties,
declarations, or conditions contained in such policies and (vi) be satisfactory
in form, substance, limits, deductibles and retention to Lessor.

<PAGE>   45

Mr. James Albrecht
August 4, 1999
Page 2

Certificates of Insurance verifying each type of coverage, signed by authorized
insurer representatives, shall be delivered to Lessor prior to closing and
prior to the expiration date of each insurance policy as evidence of the
renewal of such policies. Complete certified copies of each policy shall be
delivered to Lessor within sixty (60) days after closing and after the renewal
of each such policy.

Inasmuch as the above insurance requirements are an obligation of Lessee
throughout the Lease term, an authorized representative of Lessee must sign
below indicating agreement to provide same on behalf of Lessee.

Disbursements under the Lease will not be made until such time as Lessor has
received evidence of insurance in accordance with the above requirements as
well as the enclosed copy of this letter signed by an authorized representative
of Lessee. A copy should be retained for your reference.

Should you have any questions, I can be reached at 1-800-7-FINOVA or at my
direct number, 602-262-1536. I can also be reached by fax at 602-262-1533.

Sincerely,

FINOVA CAPITAL CORPORATION

/s/ MARY SLATTERY

Mary Slattery
Insurance Analyst

------------------------------------------------------------------------------

AGREED AND ACCEPTED THIS 3RD DAY OF SEPTEMBER, 1999

INTROGEN THERAPEUTICS, INC. ("Lessee")

BY: /s/ JAMES ALBRECHT, JR.
    -----------------------

TITLE: CHIEF FINANCIAL OFFICER
       -----------------------

cc:  Barbara Sullivan ~ FINOVA ~ CT

------------------------------------------------------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]